{"id":2429,"date":"2019-11-05T12:36:42","date_gmt":"2019-11-05T12:36:42","guid":{"rendered":"https:\/\/plaza.umin.ac.jp\/~ACP\/?p=2429"},"modified":"2019-11-05T12:36:42","modified_gmt":"2019-11-05T12:36:42","slug":"%e8%a4%87%e5%90%88%e8%aa%9e%e5%80%99%e8%a3%9citc103","status":"publish","type":"post","link":"https:\/\/plaza.umin.ac.jp\/~ACP\/2019\/11\/05\/%e8%a4%87%e5%90%88%e8%aa%9e%e5%80%99%e8%a3%9citc103.html","title":{"rendered":"\u8907\u5408\u8a9e\u5019\u88dcITC103"},"content":{"rendered":"\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
\u8907\u5408\u8a9e<\/th>\u30b9\u30b3\u30a2<\/th>\n<\/tr>\n<\/thead>\n
heart failure<\/td>11362.654529566<\/td>\n<\/tr>\n
chronic heart failure<\/td>519.90606666886<\/td>\n<\/tr>\n
symptoms of heart failure<\/td>513.21411655139<\/td>\n<\/tr>\n
n engl j med<\/td>390.00549803189<\/td>\n<\/tr>\n
heart failure hospitalization<\/td>356.42102496814<\/td>\n<\/tr>\n
congestive heart failure<\/td>280.57032391471<\/td>\n<\/tr>\n
coronary artery disease<\/td>277.15825556087<\/td>\n<\/tr>\n
j am coll cardiol<\/td>271.7851694969<\/td>\n<\/tr>\n
iv heart failure<\/td>224.04269055375<\/td>\n<\/tr>\n
systolic heart failure<\/td>187.10772077547<\/td>\n<\/tr>\n
heart rate<\/td>177.54273087838<\/td>\n<\/tr>\n
severe heart failure<\/td>171.42592868794<\/td>\n<\/tr>\n
decompensated heart failure<\/td>164.42484855543<\/td>\n<\/tr>\n
ejection fraction<\/td>164.27110467461<\/td>\n<\/tr>\n
incident heart failure<\/td>163.40050263775<\/td>\n<\/tr>\n
et al<\/td>153.3196976963<\/td>\n<\/tr>\n
management of heart failure<\/td>147.17527658401<\/td>\n<\/tr>\n
diastolic heart failure<\/td>147.17527658401<\/td>\n<\/tr>\n
american heart association<\/td>143.75766327291<\/td>\n<\/tr>\n
acute decompensated heart failure<\/td>143.51945164387<\/td>\n<\/tr>\n
new-onset heart failure<\/td>141.21630632987<\/td>\n<\/tr>\n
heart failure society of america<\/td>120.506594213<\/td>\n<\/tr>\n
incidence of heart failure<\/td>118.88245834328<\/td>\n<\/tr>\n
heart disease<\/td>115.51473789864<\/td>\n<\/tr>\n
ace inhibitors<\/td>104.12993381006<\/td>\n<\/tr>\n
myocardial infarction<\/td>97.141201813281<\/td>\n<\/tr>\n
symptomatic heart failure<\/td>95.180225031078<\/td>\n<\/tr>\n
ventricular dysfunction<\/td>91.927834917645<\/td>\n<\/tr>\n
nyha class ii<\/td>89.843380196645<\/td>\n<\/tr>\n
advanced heart failure<\/td>77.875396291055<\/td>\n<\/tr>\n
diagnosis of heart failure<\/td>76.36157006205<\/td>\n<\/tr>\n
heart failure trial<\/td>74.680896851249<\/td>\n<\/tr>\n
valsartan heart failure trial<\/td>69.316207802652<\/td>\n<\/tr>\n
suspected heart failure<\/td>68.030424883464<\/td>\n<\/tr>\n
clinical heart failure<\/td>67.671396040077<\/td>\n<\/tr>\n
structural heart disease<\/td>65.794994603193<\/td>\n<\/tr>\n
development of heart failure<\/td>64.845532444825<\/td>\n<\/tr>\n
heart work<\/td>61.502606079176<\/td>\n<\/tr>\n
risk factors<\/td>56.78140354932<\/td>\n<\/tr>\n
increased risk<\/td>55.130657644958<\/td>\n<\/tr>\n
systolic dysfunction<\/td>53.149688412681<\/td>\n<\/tr>\n
treatment of heart failure<\/td>52.64902149553<\/td>\n<\/tr>\n
heart failure patients<\/td>52.488256746022<\/td>\n<\/tr>\n
history of heart failure<\/td>49.058425528003<\/td>\n<\/tr>\n
heart failure outcomes<\/td>48.828628936152<\/td>\n<\/tr>\n
prevention of heart failure<\/td>48.828628936152<\/td>\n<\/tr>\n
common cause of heart failure<\/td>46.217324350561<\/td>\n<\/tr>\n
diastolic dysfunction<\/td>44.493513012808<\/td>\n<\/tr>\n
accf\/aha stages of heart failure<\/td>43.933256091005<\/td>\n<\/tr>\n
acute heart failure<\/td>43.291703567625<\/td>\n<\/tr>\n
ventricular hypertrophy<\/td>42.556750670457<\/td>\n<\/tr>\n
blood pressure<\/td>40.912311036161<\/td>\n<\/tr>\n
ace inhibitor<\/td>40.465445621929<\/td>\n<\/tr>\n
acute myocardial infarction<\/td>39.157846511086<\/td>\n<\/tr>\n
valvular heart disease<\/td>39.07778423469<\/td>\n<\/tr>\n
progression of heart failure<\/td>38.937698145528<\/td>\n<\/tr>\n
reduced ejection fraction<\/td>38.279943609919<\/td>\n<\/tr>\n
cardiac transplant<\/td>38.088840897721<\/td>\n<\/tr>\n
nyha class<\/td>37.168436488375<\/td>\n<\/tr>\n
systolic heart failure treatment<\/td>36.624624147531<\/td>\n<\/tr>\n
clinical trial<\/td>36.514252915594<\/td>\n<\/tr>\n
type of heart failure<\/td>36.393324585865<\/td>\n<\/tr>\n
end-stage heart failure<\/td>36.393324585865<\/td>\n<\/tr>\n
new heart failure<\/td>36.393324585865<\/td>\n<\/tr>\n
chronic systolic heart failure<\/td>36.280570898978<\/td>\n<\/tr>\n
heart failure hospitalizations<\/td>35.304076582467<\/td>\n<\/tr>\n
heart failure information<\/td>35.304076582467<\/td>\n<\/tr>\n
new york heart association<\/td>35.161605961199<\/td>\n<\/tr>\n
chronic heart failure therapy<\/td>34.119607961832<\/td>\n<\/tr>\n
heart failure exacerbations<\/td>34.015212441732<\/td>\n<\/tr>\n
mild heart failure<\/td>34.015212441732<\/td>\n<\/tr>\n
heart outcomes prevention evaluation<\/td>32.550361330155<\/td>\n<\/tr>\n
overt heart failure<\/td>32.422766222413<\/td>\n<\/tr>\n
refractory heart failure<\/td>32.422766222413<\/td>\n<\/tr>\n
standard medical therapy<\/td>32.220500574413<\/td>\n<\/tr>\n
comprehensive heart failure practice guideline<\/td>30.512498229377<\/td>\n<\/tr>\n
established heart failure<\/td>30.30410916161<\/td>\n<\/tr>\n
undiagnosed heart failure<\/td>30.30410916161<\/td>\n<\/tr>\n
preserved ejection fraction<\/td>29.847191914672<\/td>\n<\/tr>\n
primary symptoms of heart failure<\/td>29.832302124903<\/td>\n<\/tr>\n
current symptoms of heart failure<\/td>29.396302199663<\/td>\n<\/tr>\n
severe symptoms<\/td>29.302732011878<\/td>\n<\/tr>\n
chronic congestive heart failure<\/td>29.232377228144<\/td>\n<\/tr>\n
ventricular ejection fraction<\/td>29.073272214158<\/td>\n<\/tr>\n
nyha class ii heart failure<\/td>28.730557789481<\/td>\n<\/tr>\n
severe decompensated heart failure<\/td>28.487192131714<\/td>\n<\/tr>\n
butler j<\/td>27.817093114978<\/td>\n<\/tr>\n
functional cause of heart failure symptoms<\/td>27.674153402284<\/td>\n<\/tr>\n
high risk<\/td>27.565328822479<\/td>\n<\/tr>\n
severe chronic heart failure<\/td>27.381589902864<\/td>\n<\/tr>\n
coronary disease<\/td>27.162114335027<\/td>\n<\/tr>\n
nonischemic systolic heart failure<\/td>27.139328065196<\/td>\n<\/tr>\n
functional class<\/td>27.089969968019<\/td>\n<\/tr>\n
severe symptomatic heart failure<\/td>25.624331641334<\/td>\n<\/tr>\n
advanced chronic heart failure<\/td>25.481440613546<\/td>\n<\/tr>\n
non-ischemic systolic heart failure<\/td>25.460562669705<\/td>\n<\/tr>\n
severe congestive heart failure<\/td>25.289070095955<\/td>\n<\/tr>\n
renal function<\/td>25.135581073296<\/td>\n<\/tr>\n
primary cause of heart failure<\/td>24.870462797164<\/td>\n<\/tr>\n
stage c heart failure<\/td>24.649903576842<\/td>\n<\/tr>\n
all-cause mortality<\/td>24.578701598965<\/td>\n<\/tr>\n
pitt b<\/td>23.905695622382<\/td>\n<\/tr>\n
valsartan heart failure trial investigators<\/td>23.623333128789<\/td>\n<\/tr>\n
nyha class iii<\/td>23.577076175429<\/td>\n<\/tr>\n
eur heart j<\/td>23.377254482009<\/td>\n<\/tr>\n
long-term management of heart failure<\/td>23.190179526877<\/td>\n<\/tr>\n
left ventricular systolic dysfunction<\/td>22.710284630869<\/td>\n<\/tr>\n
ventricular pacing<\/td>22.70333804263<\/td>\n<\/tr>\n
african american heart failure trial<\/td>22.64064168927<\/td>\n<\/tr>\n
standard therapy<\/td>22.62189070204<\/td>\n<\/tr>\n
left ventricular dysfunction<\/td>22.095958211392<\/td>\n<\/tr>\n
family history of heart failure<\/td>22.044116795314<\/td>\n<\/tr>\n
health burden of heart failure<\/td>21.8669953659<\/td>\n<\/tr>\n
pulmonary artery pressure<\/td>21.802122352441<\/td>\n<\/tr>\n
cardiovascular death<\/td>21.65736770668<\/td>\n<\/tr>\n
myocardial ischemia<\/td>21.502111138339<\/td>\n<\/tr>\n
randomized trial of patients<\/td>21.281414946154<\/td>\n<\/tr>\n
population burden of heart failure<\/td>21.265488388788<\/td>\n<\/tr>\n
high blood pressure<\/td>20.387204864274<\/td>\n<\/tr>\n
borderline diastolic heart failure<\/td>20.214544230179<\/td>\n<\/tr>\n
physical activity<\/td>19.991995195515<\/td>\n<\/tr>\n
yusuf s<\/td>19.817003712138<\/td>\n<\/tr>\n
different stages of heart failure<\/td>19.759060825555<\/td>\n<\/tr>\n
african-american heart failure trial investigators<\/td>19.74813326343<\/td>\n<\/tr>\n
early evidence of heart failure<\/td>19.589389217353<\/td>\n<\/tr>\n
advanced end-stage heart failure<\/td>19.500538833241<\/td>\n<\/tr>\n
clinical trials<\/td>19.364606884933<\/td>\n<\/tr>\n
cases of incident heart failure<\/td>19.215537915851<\/td>\n<\/tr>\n
modifiable risk factors<\/td>19.096568395957<\/td>\n<\/tr>\n
heart catheterization<\/td>19.078208021575<\/td>\n<\/tr>\n
cardiovascular disease<\/td>18.95254888215<\/td>\n<\/tr>\n
heart failure incidence increases<\/td>18.782564580814<\/td>\n<\/tr>\n
jacc heart fail<\/td>18.673112610951<\/td>\n<\/tr>\n
treatment of preserved cardiac function heart failure<\/td>18.550149920084<\/td>\n<\/tr>\n
palliative care<\/td>18.44179994736<\/td>\n<\/tr>\n
total cost of heart failure<\/td>18.265902668449<\/td>\n<\/tr>\n
nyha functional class iii heart failure patients<\/td>18.217454040627<\/td>\n<\/tr>\n
medical therapy<\/td>17.964918147966<\/td>\n<\/tr>\n
natural progression of heart failure<\/td>17.882072954752<\/td>\n<\/tr>\n
emergency diagnosis of heart failure<\/td>17.620725961188<\/td>\n<\/tr>\n
framingham heart study<\/td>17.498080233577<\/td>\n<\/tr>\n
other risk factors<\/td>17.278687223499<\/td>\n<\/tr>\n
heart murmur<\/td>17.23910699358<\/td>\n<\/tr>\n
heart pumps<\/td>17.23910699358<\/td>\n<\/tr>\n
randomized aldactone evaluation study<\/td>17.087538022693<\/td>\n<\/tr>\n
clinical manifestations<\/td>16.83639757978<\/td>\n<\/tr>\n
american college of cardiology\/american heart association task force<\/td>16.535658500992<\/td>\n<\/tr>\n
sinus rhythm<\/td>16.413388798409<\/td>\n<\/tr>\n
rate control<\/td>16.264836064977<\/td>\n<\/tr>\n
isosorbide dinitrate<\/td>15.731731418229<\/td>\n<\/tr>\n
atrial fibrillation<\/td>14.831171004269<\/td>\n<\/tr>\n
effect of enalapril<\/td>14.810436756732<\/td>\n<\/tr>\n
reduced left ventricular ejection fractions<\/td>14.67049846495<\/td>\n<\/tr>\n
clinical practice guidelines<\/td>14.331909251528<\/td>\n<\/tr>\n
standard oral heart failure medications<\/td>14.300957322253<\/td>\n<\/tr>\n
ventricular systolic dysfunction<\/td>14.250752107168<\/td>\n<\/tr>\n
cardiac resynchronization-heart failure<\/td>14.182398182435<\/td>\n<\/tr>\n
b-type natriuretic peptide<\/td>14.104527674707<\/td>\n<\/tr>\n
seattle heart failure model<\/td>14.084936415565<\/td>\n<\/tr>\n
heart outcomes prevention evaluation study investigators<\/td>13.643378821151<\/td>\n<\/tr>\n
natriuretic peptide<\/td>13.63463239761<\/td>\n<\/tr>\n
myocardial dysfunction<\/td>13.339979404194<\/td>\n<\/tr>\n
large randomized controlled trial<\/td>13.319992037631<\/td>\n<\/tr>\n
significant difference<\/td>13.239003678587<\/td>\n<\/tr>\n
cardiac resynchronization<\/td>13.127272139645<\/td>\n<\/tr>\n
randomized trial<\/td>12.804343491775<\/td>\n<\/tr>\n
mcmurray jj<\/td>12.728649475109<\/td>\n<\/tr>\n
symptomatic patients<\/td>12.688455161287<\/td>\n<\/tr>\n
primary prevention<\/td>12.638597791832<\/td>\n<\/tr>\n
weight gain<\/td>12.358602863443<\/td>\n<\/tr>\n
pulmonary artery<\/td>12.189889456761<\/td>\n<\/tr>\n
high-risk patients<\/td>12.160801393263<\/td>\n<\/tr>\n
natriuretic peptide-guided therapy<\/td>12.148130455988<\/td>\n<\/tr>\n
presence of risk factors<\/td>12.135032696779<\/td>\n<\/tr>\n
mechanical circulatory support<\/td>12.05693358307<\/td>\n<\/tr>\n
nonischemic cardiomyopathy<\/td>11.988264044641<\/td>\n<\/tr>\n
svensson am<\/td>11.741784511603<\/td>\n<\/tr>\n
ventricular function<\/td>11.641674912519<\/td>\n<\/tr>\n
left ventricular ejection fraction<\/td>11.525563868743<\/td>\n<\/tr>\n
asymptomatic patients<\/td>11.500975876433<\/td>\n<\/tr>\n
functional capacity<\/td>11.465313506452<\/td>\n<\/tr>\n
nhlbi heart failure clinical research network<\/td>11.358108274759<\/td>\n<\/tr>\n
survival study<\/td>11.233623397695<\/td>\n<\/tr>\n
icd implantation<\/td>11.19016562612<\/td>\n<\/tr>\n
jessup m. stage b heart failure<\/td>11.118430014839<\/td>\n<\/tr>\n
eplerenone post-acute myocardial infarction heart failure efficacy<\/td>10.997210408437<\/td>\n<\/tr>\n
hospitalization rates<\/td>10.954451150103<\/td>\n<\/tr>\n
global myocardial ischemia<\/td>10.912809166167<\/td>\n<\/tr>\n
systolic blood pressure<\/td>10.88520498932<\/td>\n<\/tr>\n
ventricular volume<\/td>10.702456190343<\/td>\n<\/tr>\n
quality of life<\/td>10.669676460234<\/td>\n<\/tr>\n
physical examination<\/td>10.602356529148<\/td>\n<\/tr>\n
microvascular disease<\/td>10.487221590056<\/td>\n<\/tr>\n
right heart catheterization<\/td>10.4799301148<\/td>\n<\/tr>\n
specific causes<\/td>10.392304845413<\/td>\n<\/tr>\n
bozkurt b<\/td>10.392304845413<\/td>\n<\/tr>\n
trial investigators<\/td>10.388739120117<\/td>\n<\/tr>\n
reduced risk<\/td>10.261558002989<\/td>\n<\/tr>\n
controlled trial<\/td>10.182919580087<\/td>\n<\/tr>\n
nyha functional classification<\/td>10.142555229712<\/td>\n<\/tr>\n
clinical practice<\/td>10.102415878263<\/td>\n<\/tr>\n
pulmonary disease<\/td>10.019940278469<\/td>\n<\/tr>\n
cardiovascular mortality<\/td>9.9312951847935<\/td>\n<\/tr>\n
inotropic agents<\/td>9.7291971163912<\/td>\n<\/tr>\n
clinical outcomes<\/td>9.6522804347375<\/td>\n<\/tr>\n
moderate symptoms<\/td>9.6411410273358<\/td>\n<\/tr>\n
systolic blood pressure intervention trial<\/td>9.6084651563334<\/td>\n<\/tr>\n
aldosterone antagonist<\/td>9.603257618831<\/td>\n<\/tr>\n
study investigators<\/td>9.5876942772625<\/td>\n<\/tr>\n
current guidelines<\/td>9.5803106027242<\/td>\n<\/tr>\n
intravenous inotropic agents<\/td>9.5374267604657<\/td>\n<\/tr>\n
acute coronary syndrome<\/td>9.4985091341904<\/td>\n<\/tr>\n
american college of cardiology foundation<\/td>9.3845904936053<\/td>\n<\/tr>\n
controlled trial of patients<\/td>9.1337089660923<\/td>\n<\/tr>\n
american heart association statistics committee<\/td>8.9787339517073<\/td>\n<\/tr>\n
coronary revascularization<\/td>8.9720926873273<\/td>\n<\/tr>\n
cohn jn<\/td>8.9442719099992<\/td>\n<\/tr>\n
other causes<\/td>8.9442719099992<\/td>\n<\/tr>\n
induced coronary artery disease<\/td>8.847853494422<\/td>\n<\/tr>\n
specific cause<\/td>8.8186670410496<\/td>\n<\/tr>\n
disease control<\/td>8.8186670410496<\/td>\n<\/tr>\n
circ heart fail<\/td>8.7264615096001<\/td>\n<\/tr>\n
angiotensin receptor?neprilysin inhibitor<\/td>8.7211839342619<\/td>\n<\/tr>\n
survival study investigators<\/td>8.6332728113428<\/td>\n<\/tr>\n
wilson j<\/td>8.6289073396314<\/td>\n<\/tr>\n
young j<\/td>8.6289073396314<\/td>\n<\/tr>\n
lindenfeld j<\/td>8.6289073396314<\/td>\n<\/tr>\n
consensus trial study group<\/td>8.5920924788324<\/td>\n<\/tr>\n
symptomatic nyha class ii<\/td>8.5915760184806<\/td>\n<\/tr>\n
ace inhibitor therapy<\/td>8.5800543746011<\/td>\n<\/tr>\n
systemic disease<\/td>8.5291344178582<\/td>\n<\/tr>\n
effect of carvedilol<\/td>8.5242951907087<\/td>\n<\/tr>\n
krishnaswamy p<\/td>8.4852813742386<\/td>\n<\/tr>\n
cardiovascular disease hospitalization<\/td>8.4455351182242<\/td>\n<\/tr>\n
low cardiac output<\/td>8.4200214932682<\/td>\n<\/tr>\n
third heart sound<\/td>8.4078800764062<\/td>\n<\/tr>\n
initial laboratory evaluation<\/td>8.3925789638182<\/td>\n<\/tr>\n
evaluation of patients<\/td>8.3725700160278<\/td>\n<\/tr>\n
casey de jr<\/td>8.2985253256109<\/td>\n<\/tr>\n
randomised trial<\/td>8.1812469784701<\/td>\n<\/tr>\n
cardiac-resynchronization therapy<\/td>8.1739324901763<\/td>\n<\/tr>\n
usual care<\/td>8.1221727394757<\/td>\n<\/tr>\n
adverse changes<\/td>8.1072009288422<\/td>\n<\/tr>\n
reduced mortality<\/td>8.0770059874436<\/td>\n<\/tr>\n
ischemic cardiomyopathy<\/td>7.9921760297609<\/td>\n<\/tr>\n
angiotensin-converting enzyme<\/td>7.9774438454175<\/td>\n<\/tr>\n
lee kl<\/td>7.8964440777149<\/td>\n<\/tr>\n
champion trial study group<\/td>7.8789835426777<\/td>\n<\/tr>\n
6-minute walk test<\/td>7.845962916071<\/td>\n<\/tr>\n
haarbo j<\/td>7.7970979610547<\/td>\n<\/tr>\n
neaton j<\/td>7.7970979610547<\/td>\n<\/tr>\n
pogue j<\/td>7.7970979610547<\/td>\n<\/tr>\n
emberson j<\/td>7.7970979610547<\/td>\n<\/tr>\n
bosch j<\/td>7.7970979610547<\/td>\n<\/tr>\n
mccord j<\/td>7.7970979610547<\/td>\n<\/tr>\n
gong j<\/td>7.7970979610547<\/td>\n<\/tr>\n
gallagher j<\/td>7.7970979610547<\/td>\n<\/tr>\n
mathew j<\/td>7.7970979610547<\/td>\n<\/tr>\n
care of patients<\/td>7.7844093950776<\/td>\n<\/tr>\n
randomized aldactone evaluation study investigators<\/td>7.7057858141598<\/td>\n<\/tr>\n
poor functional status<\/td>7.5438910962342<\/td>\n<\/tr>\n
angiotensin receptor?neprilysin inhibitors<\/td>7.5417066766768<\/td>\n<\/tr>\n
right ventricular function<\/td>7.5395190889965<\/td>\n<\/tr>\n
clinical guidelines<\/td>7.5352689577953<\/td>\n<\/tr>\n
implantable pulmonary artery pressure<\/td>7.5053420380578<\/td>\n<\/tr>\n
cardiomems heart sensor<\/td>7.490569582348<\/td>\n<\/tr>\n
left ventricular hypertrophy<\/td>7.4659422745248<\/td>\n<\/tr>\n
cardiac resynchronization therapy<\/td>7.461797978668<\/td>\n<\/tr>\n
acute pulmonary disease<\/td>7.4527789849152<\/td>\n<\/tr>\n
glycemic control<\/td>7.4448388728168<\/td>\n<\/tr>\n
randomized trial danish<\/td>7.377854493525<\/td>\n<\/tr>\n
american college of cardiology foundation\/american heart association task force<\/td>7.3615515350663<\/td>\n<\/tr>\n
other risk factor<\/td>7.3557314102613<\/td>\n<\/tr>\n
20,985 patients<\/td>7.3484692283495<\/td>\n<\/tr>\n
swedberg k<\/td>7.3484692283495<\/td>\n<\/tr>\n
blood volume<\/td>7.3256830029694<\/td>\n<\/tr>\n
first hospitalization<\/td>7.3256830029694<\/td>\n<\/tr>\n
primary risk factors<\/td>7.2867046089153<\/td>\n<\/tr>\n
inhibitor ivabradine trial<\/td>7.2716336769238<\/td>\n<\/tr>\n
renal disease<\/td>7.2560172494525<\/td>\n<\/tr>\n
functional class guides treatment<\/td>7.2225756445557<\/td>\n<\/tr>\n
quality of care<\/td>7.2217462736946<\/td>\n<\/tr>\n
observational study<\/td>7.1407419177511<\/td>\n<\/tr>\n
zannad f<\/td>7.1352426900163<\/td>\n<\/tr>\n
subset of patients<\/td>7.1352426900163<\/td>\n<\/tr>\n
cardiovascular events<\/td>7.1131176401557<\/td>\n<\/tr>\n
medical history<\/td>7.0851677179898<\/td>\n<\/tr>\n
clinical studies<\/td>7.0568830507494<\/td>\n<\/tr>\n
disease progression<\/td>6.9009799013736<\/td>\n<\/tr>\n
advanced disease<\/td>6.9009799013736<\/td>\n<\/tr>\n
volume overload<\/td>6.8795812565008<\/td>\n<\/tr>\n
natriuretic peptide levels<\/td>6.7807496594118<\/td>\n<\/tr>\n
loop diuretics<\/td>6.700737917669<\/td>\n<\/tr>\n
clinical status<\/td>6.673987930963<\/td>\n<\/tr>\n
effects of treatment<\/td>6.6706214794855<\/td>\n<\/tr>\n
ventricular size<\/td>6.6604914252356<\/td>\n<\/tr>\n
danish study<\/td>6.6452091262532<\/td>\n<\/tr>\n
implantable cardioverter-defibrillator<\/td>6.6400915182019<\/td>\n<\/tr>\n
angiotensin-receptor blockers<\/td>6.6400915182019<\/td>\n<\/tr>\n
kazanegra r<\/td>6.6195018392937<\/td>\n<\/tr>\n
prophylactic implantation<\/td>6.6195018392937<\/td>\n<\/tr>\n
boineau r<\/td>6.6195018392937<\/td>\n<\/tr>\n
latini r<\/td>6.6195018392937<\/td>\n<\/tr>\n
outcomes of patients<\/td>6.5934915059146<\/td>\n<\/tr>\n
range of risk factor levels<\/td>6.558071028175<\/td>\n<\/tr>\n
american college of cardiology<\/td>6.5412422314049<\/td>\n<\/tr>\n
effects of candesartan<\/td>6.4474195909412<\/td>\n<\/tr>\n
usual clinical care<\/td>6.3802363071573<\/td>\n<\/tr>\n
major risk factors<\/td>6.3655227986524<\/td>\n<\/tr>\n
miracle icd trial<\/td>6.3547610473256<\/td>\n<\/tr>\n
history of hospitalization<\/td>6.3442275806434<\/td>\n<\/tr>\n
adverse effects<\/td>6.3442275806434<\/td>\n<\/tr>\n
cannom ds<\/td>6.3442275806434<\/td>\n<\/tr>\n
cardiac insufficiency bisoprolol study ii<\/td>6.3179627563086<\/td>\n<\/tr>\n
multicenter insync icd randomized clinical evaluation<\/td>6.3095633402878<\/td>\n<\/tr>\n
relative risk<\/td>6.3086842910598<\/td>\n<\/tr>\n
lifetime risk<\/td>6.3086842910598<\/td>\n<\/tr>\n
risk score<\/td>6.3086842910598<\/td>\n<\/tr>\n
atherosclerosis risk<\/td>6.3086842910598<\/td>\n<\/tr>\n
influence risk<\/td>6.3086842910598<\/td>\n<\/tr>\n
accf\/aha guideline<\/td>6.2926925672916<\/td>\n<\/tr>\n
functional capacity of patients<\/td>6.2273448933373<\/td>\n<\/tr>\n
left-ventricular ejection fraction<\/td>6.2133136519014<\/td>\n<\/tr>\n
accf\/aha guidelines<\/td>6.1771812387753<\/td>\n<\/tr>\n
subjective symptoms<\/td>6.160140576482<\/td>\n<\/tr>\n
serum digoxin levels<\/td>6.1273116840957<\/td>\n<\/tr>\n
klein h<\/td>6.1256286272176<\/td>\n<\/tr>\n
renal insufficiency<\/td>6.1256286272176<\/td>\n<\/tr>\n
effect of digoxin<\/td>6.1015588940837<\/td>\n<\/tr>\n
modification of risk factors<\/td>6.0675163483893<\/td>\n<\/tr>\n
other patients<\/td>6.0615465140299<\/td>\n<\/tr>\n
ventricular dyssynchrony<\/td>6.0184333968691<\/td>\n<\/tr>\n
ventricular arrhythmias<\/td>6.0184333968691<\/td>\n<\/tr>\n
ventricular enlargement<\/td>6.0184333968691<\/td>\n<\/tr>\n
stevenson lw<\/td>6<\/td>\n<\/tr>\n
shortness of breath<\/td>6<\/td>\n<\/tr>\n
such cardiovascular risk factors<\/td>5.9621371715169<\/td>\n<\/tr>\n
valvular disease<\/td>5.957892135529<\/td>\n<\/tr>\n
solvd investigators<\/td>5.9436557324017<\/td>\n<\/tr>\n
val-heft investigators<\/td>5.9436557324017<\/td>\n<\/tr>\n
charm investigators<\/td>5.9436557324017<\/td>\n<\/tr>\n
term gheart failure h<\/td>5.9368741417647<\/td>\n<\/tr>\n
clinical syndrome<\/td>5.9341076602399<\/td>\n<\/tr>\n
dietary sodium restriction<\/td>5.9191344907092<\/td>\n<\/tr>\n
controlled clinical trials<\/td>5.8878964084292<\/td>\n<\/tr>\n
cardiogenic shock<\/td>5.8856619127654<\/td>\n<\/tr>\n
other mechanisms<\/td>5.8856619127654<\/td>\n<\/tr>\n
previous myocardial infarction<\/td>5.8653533983426<\/td>\n<\/tr>\n
other adverse effects<\/td>5.8601559088987<\/td>\n<\/tr>\n
elevated systemic blood pressure<\/td>5.8538734383683<\/td>\n<\/tr>\n
significant differences<\/td>5.8259012604879<\/td>\n<\/tr>\n
oral diuretic therapy<\/td>5.8249031191339<\/td>\n<\/tr>\n
monitoring of pressure<\/td>5.8106700157786<\/td>\n<\/tr>\n
myocardial remodeling<\/td>5.7991674783197<\/td>\n<\/tr>\n
myocardial structure<\/td>5.7991674783197<\/td>\n<\/tr>\n
cardiovascular outcomes<\/td>5.7850152170382<\/td>\n<\/tr>\n
j card fail<\/td>5.7714994741381<\/td>\n<\/tr>\n
exercise capacity<\/td>5.7326567532262<\/td>\n<\/tr>\n
symptomatic management<\/td>5.7326567532262<\/td>\n<\/tr>\n
champion trial investigators<\/td>5.717797486992<\/td>\n<\/tr>\n
harrison a<\/td>5.7005397655436<\/td>\n<\/tr>\n
krum h<\/td>5.7005397655436<\/td>\n<\/tr>\n
rawshani a<\/td>5.7005397655436<\/td>\n<\/tr>\n
recognized risk factors<\/td>5.6710361016125<\/td>\n<\/tr>\n
nonmodifiable risk factors<\/td>5.6710361016125<\/td>\n<\/tr>\n
intensive blood pressure<\/td>5.6586941766333<\/td>\n<\/tr>\n
low doses<\/td>5.5663153674275<\/td>\n<\/tr>\n
packer m<\/td>5.5663153674275<\/td>\n<\/tr>\n
rates of hyperkalemia<\/td>5.5663153674275<\/td>\n<\/tr>\n
jessup m<\/td>5.5663153674275<\/td>\n<\/tr>\n
important adverse effects<\/td>5.547933582892<\/td>\n<\/tr>\n
daily pulmonary artery pressure readings<\/td>5.5321413028549<\/td>\n<\/tr>\n
cardiac toxicity<\/td>5.5193380421438<\/td>\n<\/tr>\n
cardiac output<\/td>5.5193380421438<\/td>\n<\/tr>\n
nonfatal myocardial infarction<\/td>5.4820834359262<\/td>\n<\/tr>\n
rates of hospitalization<\/td>5.4772255750517<\/td>\n<\/tr>\n
charm-preserved trial<\/td>5.4711295994695<\/td>\n<\/tr>\n
charm-alternative trial<\/td>5.4711295994695<\/td>\n<\/tr>\n
cardiac pump function<\/td>5.442323265122<\/td>\n<\/tr>\n
non-ischemic cardiomyopathy treatment evaluation<\/td>5.438910834863<\/td>\n<\/tr>\n
symptoms of volume overload<\/td>5.4146047111091<\/td>\n<\/tr>\n
advanced therapy<\/td>5.3787500669746<\/td>\n<\/tr>\n
large population study<\/td>5.3481384667782<\/td>\n<\/tr>\n
masson s<\/td>5.3446902355676<\/td>\n<\/tr>\n
barlera s<\/td>5.3446902355676<\/td>\n<\/tr>\n
madit-crt trial investigators<\/td>5.3441695264733<\/td>\n<\/tr>\n
prospective randomized cumulative survival study group<\/td>5.3249941204811<\/td>\n<\/tr>\n
gerdes am<\/td>5.3049500053196<\/td>\n<\/tr>\n
kucharska-newton am<\/td>5.3049500053196<\/td>\n<\/tr>\n
significant effect<\/td>5.3049500053196<\/td>\n<\/tr>\n
emphasis-hf study group<\/td>5.2974318574102<\/td>\n<\/tr>\n
held p<\/td>5.26429605181<\/td>\n<\/tr>\n
jourdain p<\/td>5.26429605181<\/td>\n<\/tr>\n
magnetic resonance imaging<\/td>5.2414827884178<\/td>\n<\/tr>\n
myocardial sarcomere<\/td>5.2401393526787<\/td>\n<\/tr>\n
clinical characteristics<\/td>5.2226777991727<\/td>\n<\/tr>\n
clinical benefit<\/td>5.2226777991727<\/td>\n<\/tr>\n
clinical assessment<\/td>5.2226777991727<\/td>\n<\/tr>\n
ventricular noncompaction cardiomyopathy results<\/td>5.200849059796<\/td>\n<\/tr>\n
optimal medical therapy<\/td>5.1893987221281<\/td>\n<\/tr>\n
mild symptoms<\/td>5.1800401282227<\/td>\n<\/tr>\n
functional status<\/td>5.1800401282227<\/td>\n<\/tr>\n
blood tests<\/td>5.1800401282227<\/td>\n<\/tr>\n
weight monitoring<\/td>5.1800401282227<\/td>\n<\/tr>\n
hypomagnesemia increase risk<\/td>5.1660198496359<\/td>\n<\/tr>\n
sudden death<\/td>5.1510191538028<\/td>\n<\/tr>\n
cardiac muscle<\/td>5.1363228010461<\/td>\n<\/tr>\n
cardiac structure<\/td>5.1363228010461<\/td>\n<\/tr>\n
digoxin dose<\/td>5.0914597900437<\/td>\n<\/tr>\n
ventricular dysfunction delays onset<\/td>5.0761464007087<\/td>\n<\/tr>\n
left-ventricular systolic function<\/td>5.0719730249202<\/td>\n<\/tr>\n
multinational study investigators<\/td>5.0657970191009<\/td>\n<\/tr>\n
multicenter automatic defibrillator implantation trial ii investigators<\/td>5.0514818398486<\/td>\n<\/tr>\n
elderly study<\/td>5.0492670327448<\/td>\n<\/tr>\n
effects of enalapril<\/td>5.0453784915223<\/td>\n<\/tr>\n
maladaptive ventricular hypertrophy<\/td>5.0063266198115<\/td>\n<\/tr>\n
enalapril group<\/td>4.9737947036147<\/td>\n<\/tr>\n
high risk of re-admission<\/td>4.9241689779833<\/td>\n<\/tr>\n
patient's clinical status<\/td>4.9027522910779<\/td>\n<\/tr>\n
randomised trial of losartan<\/td>4.8760319739572<\/td>\n<\/tr>\n
quality measures<\/td>4.8645985581956<\/td>\n<\/tr>\n
fluid restriction<\/td>4.8645985581956<\/td>\n<\/tr>\n
therapy changes<\/td>4.8602493374348<\/td>\n<\/tr>\n
drug therapy<\/td>4.8602493374348<\/td>\n<\/tr>\n
randomised placebo-controlled study<\/td>4.8490562872798<\/td>\n<\/tr>\n
increase exercise capacity<\/td>4.8465663976689<\/td>\n<\/tr>\n
ace inhibitor ramipril<\/td>4.8409406455445<\/td>\n<\/tr>\n
practice guidelines<\/td>4.8339055525626<\/td>\n<\/tr>\n
diabetes care<\/td>4.8294728055328<\/td>\n<\/tr>\n
independent risk factor<\/td>4.8284476525076<\/td>\n<\/tr>\n
absence of symptoms<\/td>4.8205705136679<\/td>\n<\/tr>\n
loop diuretic<\/td>4.8205705136679<\/td>\n<\/tr>\n
refractory symptoms<\/td>4.8205705136679<\/td>\n<\/tr>\n
pressure overload<\/td>4.8026164940938<\/td>\n<\/tr>\n
other factors<\/td>4.7867398586908<\/td>\n<\/tr>\n
sprint research study group<\/td>4.7637250806784<\/td>\n<\/tr>\n
disease process<\/td>4.7381372205376<\/td>\n<\/tr>\n
reduced diastolic<\/td>4.7381372205376<\/td>\n<\/tr>\n
lung disease<\/td>4.7381372205376<\/td>\n<\/tr>\n
clinical suggestions<\/td>4.7192221235411<\/td>\n<\/tr>\n
clinical suspicion<\/td>4.7192221235411<\/td>\n<\/tr>\n
african american patients<\/td>4.7170518987602<\/td>\n<\/tr>\n
large double-blind trial<\/td>4.6980201586465<\/td>\n<\/tr>\n
tognoni g<\/td>4.6806946386414<\/td>\n<\/tr>\n
ischemic stroke<\/td>4.6806946386414<\/td>\n<\/tr>\n
pulmonary causes of exercise limitation<\/td>4.6806946386414<\/td>\n<\/tr>\n
sudden cardiac death<\/td>4.6575419678526<\/td>\n<\/tr>\n
cardiac sarcoidosis<\/td>4.6411915742122<\/td>\n<\/tr>\n
cardiac involvement<\/td>4.6411915742122<\/td>\n<\/tr>\n
cardiac workload<\/td>4.6411915742122<\/td>\n<\/tr>\n
cardiac valves<\/td>4.6411915742122<\/td>\n<\/tr>\n
cardiac amyloidosis<\/td>4.6411915742122<\/td>\n<\/tr>\n
cause of death<\/td>4.6361821858297<\/td>\n<\/tr>\n
stars-bnp multicenter study<\/td>4.6220442888931<\/td>\n<\/tr>\n
mild patients hospitalization<\/td>4.6196709652247<\/td>\n<\/tr>\n
chronic atrial fibrillation<\/td>4.6132323629156<\/td>\n<\/tr>\n
association of serum digoxin concentration<\/td>4.5916055846449<\/td>\n<\/tr>\n
patient's nyha<\/td>4.5825756949558<\/td>\n<\/tr>\n
k?ber l<\/td>4.5590141139096<\/td>\n<\/tr>\n
effects of valsartan<\/td>4.5590141139096<\/td>\n<\/tr>\n
combination of ace inhibitors<\/td>4.5582562960338<\/td>\n<\/tr>\n
coronary angiography<\/td>4.4860463436637<\/td>\n<\/tr>\n
metoprolol cr\/xl randomised intervention trial<\/td>4.4287921839498<\/td>\n<\/tr>\n
diabetes mellitus<\/td>4.4267276788013<\/td>\n<\/tr>\n
inefficient ventricular contractile function<\/td>4.4248034309981<\/td>\n<\/tr>\n
family history of cardiomyopathy<\/td>4.4088173933227<\/td>\n<\/tr>\n
initial evaluation<\/td>4.3679267425564<\/td>\n<\/tr>\n
prospective clinical trials<\/td>4.3678557314809<\/td>\n<\/tr>\n
bnp levels<\/td>4.3558771746929<\/td>\n<\/tr>\n
severity of symptoms<\/td>4.3558771746929<\/td>\n<\/tr>\n
oral diuretic dose<\/td>4.3440506352097<\/td>\n<\/tr>\n
other measures<\/td>4.3253077270721<\/td>\n<\/tr>\n
american college of physicians<\/td>4.3231140296575<\/td>\n<\/tr>\n
left-ventricular dysfunction<\/td>4.2813902858562<\/td>\n<\/tr>\n
conduction abnormalities<\/td>4.2813902858562<\/td>\n<\/tr>\n
givertz mm<\/td>4.2813902858562<\/td>\n<\/tr>\n
maladaptive ventricular remodeling<\/td>4.2513258303959<\/td>\n<\/tr>\n
prophylactic icd implantation<\/td>4.2484406376281<\/td>\n<\/tr>\n
other important guidelines<\/td>4.2448203141176<\/td>\n<\/tr>\n
right ventricular free wall<\/td>4.2425598510497<\/td>\n<\/tr>\n
composite outcome<\/td>4.2294850537623<\/td>\n<\/tr>\n
daubert jp<\/td>4.2294850537623<\/td>\n<\/tr>\n
plasma digoxin levels<\/td>4.2227675591121<\/td>\n<\/tr>\n
peripartum cardiomyopathy<\/td>4.1824461364775<\/td>\n<\/tr>\n
other systemic disorders<\/td>4.1689486953466<\/td>\n<\/tr>\n
cooperative north scandinavian enalapril survival study<\/td>4.1683924274728<\/td>\n<\/tr>\n
oral furosemide therapy<\/td>4.1633714773242<\/td>\n<\/tr>\n
recent observational study<\/td>4.1623049031538<\/td>\n<\/tr>\n
prophylactic icd<\/td>4.1408245796559<\/td>\n<\/tr>\n
objective measures of disease status<\/td>4.1301657152851<\/td>\n<\/tr>\n
sinus rate<\/td>4.1195342878142<\/td>\n<\/tr>\n
oxygen-rich blood<\/td>4.1195342878142<\/td>\n<\/tr>\n
blood flow<\/td>4.1195342878142<\/td>\n<\/tr>\n
blood counts<\/td>4.1195342878142<\/td>\n<\/tr>\n
reduced rates<\/td>4.090623489235<\/td>\n<\/tr>\n
\u00c3\u00a0-blocker therapy<\/td>4.0869662450882<\/td>\n<\/tr>\n
first-line therapy<\/td>4.0869662450882<\/td>\n<\/tr>\n
appropriate therapy<\/td>4.0869662450882<\/td>\n<\/tr>\n
evaluation of losartan<\/td>4.0648138508249<\/td>\n<\/tr>\n
other important disorders<\/td>4.0632051688874<\/td>\n<\/tr>\n
routine care<\/td>4.0610863697379<\/td>\n<\/tr>\n
specific clinical indication<\/td>4.0577694145156<\/td>\n<\/tr>\n
exercise training<\/td>4.0536004644211<\/td>\n<\/tr>\n
role of palliative care<\/td>4.0300296715324<\/td>\n<\/tr>\n
maisel as<\/td>4<\/td>\n<\/tr>\n
gbridge therapy h<\/td>3.9993486932656<\/td>\n<\/tr>\n
pressure-guided management of patients<\/td>3.9654064565002<\/td>\n<\/tr>\n
serum levels of electrolytes<\/td>3.9468319327726<\/td>\n<\/tr>\n
moss aj<\/td>3.9359793425309<\/td>\n<\/tr>\n
staging system<\/td>3.9359793425309<\/td>\n<\/tr>\n
ezekowitz ja<\/td>3.9359793425309<\/td>\n<\/tr>\n
defibrillator implantation<\/td>3.9359793425309<\/td>\n<\/tr>\n
fluid retention<\/td>3.9359793425309<\/td>\n<\/tr>\n
patient information<\/td>3.9359793425309<\/td>\n<\/tr>\n
controlled studies<\/td>3.9359793425309<\/td>\n<\/tr>\n
gventricular dysfunction h<\/td>3.9320768183025<\/td>\n<\/tr>\n
effect of diuretics<\/td>3.8985489805273<\/td>\n<\/tr>\n
left bundle branch block<\/td>3.8735854825302<\/td>\n<\/tr>\n
adverse events<\/td>3.8729833462074<\/td>\n<\/tr>\n
pulmonary capillary wedge pressure<\/td>3.8536671042695<\/td>\n<\/tr>\n
arni treatment<\/td>3.8512851068431<\/td>\n<\/tr>\n
goal of treatment<\/td>3.8512851068431<\/td>\n<\/tr>\n
early treatment<\/td>3.8512851068431<\/td>\n<\/tr>\n
potential adverse effects<\/td>3.8467222990467<\/td>\n<\/tr>\n
intolerable adverse effects<\/td>3.8467222990467<\/td>\n<\/tr>\n
continuous intravenous inotropic agents<\/td>3.8375885893579<\/td>\n<\/tr>\n
carvedilol post-infarct survival control<\/td>3.8375885893579<\/td>\n<\/tr>\n
lo studio della streptochinasi nell finfarto miocardico-heart failure trial<\/td>3.8349221943338<\/td>\n<\/tr>\n
laboratory evidence<\/td>3.8067540958393<\/td>\n<\/tr>\n
peripheral vascular disease<\/td>3.8027429028336<\/td>\n<\/tr>\n
houston-miller n<\/td>3.7976578442319<\/td>\n<\/tr>\n
kagiyama n<\/td>3.7976578442319<\/td>\n<\/tr>\n
freemantle n<\/td>3.7976578442319<\/td>\n<\/tr>\n
heterogeneous study populations<\/td>3.7817049765835<\/td>\n<\/tr>\n
ivabradine group<\/td>3.7792667089114<\/td>\n<\/tr>\n
basic palliative care<\/td>3.7666884513457<\/td>\n<\/tr>\n
palliative care addresses<\/td>3.7666884513457<\/td>\n<\/tr>\n
aha stage c<\/td>3.7578442412245<\/td>\n<\/tr>\n
specific type of cardiomyopathy<\/td>3.7439265731403<\/td>\n<\/tr>\n
other treatment decisions<\/td>3.7430197238696<\/td>\n<\/tr>\n
patient's daily weight<\/td>3.7288210710016<\/td>\n<\/tr>\n
hall wj<\/td>3.7224194364084<\/td>\n<\/tr>\n
qrs duration<\/td>3.7224194364084<\/td>\n<\/tr>\n
bauman jg<\/td>3.7224194364084<\/td>\n<\/tr>\n
muscular dystrophy<\/td>3.7224194364084<\/td>\n<\/tr>\n
abraham wt<\/td>3.7224194364084<\/td>\n<\/tr>\n
larson mg<\/td>3.7224194364084<\/td>\n<\/tr>\n
pfeffer ma<\/td>3.7224194364084<\/td>\n<\/tr>\n
incessant tachycardia<\/td>3.7224194364084<\/td>\n<\/tr>\n
yancy cw<\/td>3.7224194364084<\/td>\n<\/tr>\n
bourge rc<\/td>3.7224194364084<\/td>\n<\/tr>\n
intravenous loop diuretics<\/td>3.719046769829<\/td>\n<\/tr>\n
global mortality<\/td>3.7126875376323<\/td>\n<\/tr>\n
adequate doses of ace inhibitors<\/td>3.7098517435797<\/td>\n<\/tr>\n
population-based reykjavik study<\/td>3.708192102729<\/td>\n<\/tr>\n
only therapy<\/td>3.6929908877475<\/td>\n<\/tr>\n
ordinary physical activity<\/td>3.6830484346607<\/td>\n<\/tr>\n
invasive evaluation<\/td>3.6729739399065<\/td>\n<\/tr>\n
safety of exercise training<\/td>3.6666352749723<\/td>\n<\/tr>\n
advanced stages<\/td>3.6628415014847<\/td>\n<\/tr>\n
b-type natriuretic peptide assay<\/td>3.6628415014847<\/td>\n<\/tr>\n
supervised exercise<\/td>3.6628415014847<\/td>\n<\/tr>\n
a1c levels<\/td>3.6628415014847<\/td>\n<\/tr>\n
other noninvasive imaging<\/td>3.6590516533172<\/td>\n<\/tr>\n
effect of metoprolol cr\/xl<\/td>3.6529276674218<\/td>\n<\/tr>\n
european society of cardiology<\/td>3.6467519140054<\/td>\n<\/tr>\n
direct myocardial toxin?it<\/td>3.6231148419824<\/td>\n<\/tr>\n
increased mortality<\/td>3.6161715709604<\/td>\n<\/tr>\n
regional dysfunction<\/td>3.6002057436785<\/td>\n<\/tr>\n
sodium restriction<\/td>3.6002057436785<\/td>\n<\/tr>\n
digoxin toxicity<\/td>3.6002057436785<\/td>\n<\/tr>\n
serum level<\/td>3.6002057436785<\/td>\n<\/tr>\n
controlled trials<\/td>3.6002057436785<\/td>\n<\/tr>\n
inhibitor ramipril<\/td>3.5840246342157<\/td>\n<\/tr>\n
angiotensin-converting-enzyme inhibitor<\/td>3.5840246342157<\/td>\n<\/tr>\n
variety of patients<\/td>3.5676213450082<\/td>\n<\/tr>\n
arrhythmogenic right ventricular dysplasia<\/td>3.567553370247<\/td>\n<\/tr>\n
elevated total cholesterol levels<\/td>3.5620857880302<\/td>\n<\/tr>\n
health care costs<\/td>3.561271038656<\/td>\n<\/tr>\n
cardiovascular system<\/td>3.5565588200778<\/td>\n<\/tr>\n
volume status<\/td>3.5565588200778<\/td>\n<\/tr>\n
clinical slide set<\/td>3.5447880909253<\/td>\n<\/tr>\n
ability of icd implantation<\/td>3.5376050502214<\/td>\n<\/tr>\n
danish investigators<\/td>3.5341188430494<\/td>\n<\/tr>\n
renal excretion of digoxin<\/td>3.503082197055<\/td>\n<\/tr>\n
other medications<\/td>3.4996355115806<\/td>\n<\/tr>\n
other \u00c3\u00a0-blockers<\/td>3.4996355115806<\/td>\n<\/tr>\n
other lifestyle changes<\/td>3.4877505632064<\/td>\n<\/tr>\n
miracle icd<\/td>3.4820045452271<\/td>\n<\/tr>\n
appropriate serum level of digoxin<\/td>3.473041544387<\/td>\n<\/tr>\n
hemodynamically significant ventricular septal defects<\/td>3.4683547086532<\/td>\n<\/tr>\n
felker gm<\/td>3.4641016151377<\/td>\n<\/tr>\n
cigarette smoking<\/td>3.4641016151377<\/td>\n<\/tr>\n
benjamin ej<\/td>3.4641016151377<\/td>\n<\/tr>\n
granger cb<\/td>3.4641016151377<\/td>\n<\/tr>\n
brown mw<\/td>3.4641016151377<\/td>\n<\/tr>\n
family history<\/td>3.4641016151377<\/td>\n<\/tr>\n
end-organ hypoperfusion<\/td>3.4641016151377<\/td>\n<\/tr>\n
davis ce<\/td>3.4641016151377<\/td>\n<\/tr>\n
few days<\/td>3.4641016151377<\/td>\n<\/tr>\n
stable weight<\/td>3.4641016151377<\/td>\n<\/tr>\n
united states<\/td>3.4641016151377<\/td>\n<\/tr>\n
hiv infection<\/td>3.4641016151377<\/td>\n<\/tr>\n
d fagostino r jr<\/td>3.4519247197843<\/td>\n<\/tr>\n
first-line drug therapy<\/td>3.4458199066465<\/td>\n<\/tr>\n
nondiabetic control group<\/td>3.4312578792284<\/td>\n<\/tr>\n
other relevant pqrs quality measures<\/td>3.4278736200193<\/td>\n<\/tr>\n
spironolactone group<\/td>3.4149529703483<\/td>\n<\/tr>\n
collaborative care<\/td>3.4149529703483<\/td>\n<\/tr>\n
guided care<\/td>3.4149529703483<\/td>\n<\/tr>\n
decrease hospitalization<\/td>3.4086580994025<\/td>\n<\/tr>\n
bundle branch block<\/td>3.3967626591299<\/td>\n<\/tr>\n
effect of spironolactone<\/td>3.3895612242702<\/td>\n<\/tr>\n
trabeculated myocardial architecture<\/td>3.3863633634254<\/td>\n<\/tr>\n
aha stage<\/td>3.3635856610149<\/td>\n<\/tr>\n
use of bnp<\/td>3.3635856610149<\/td>\n<\/tr>\n
prophylactic defibrillator implantation<\/td>3.3604214537127<\/td>\n<\/tr>\n
other performance measures<\/td>3.3446807651574<\/td>\n<\/tr>\n
other tests<\/td>3.3437015248821<\/td>\n<\/tr>\n
meta-analysis global group<\/td>3.3285607270274<\/td>\n<\/tr>\n
cardiopulmonary exercise test<\/td>3.3244690547396<\/td>\n<\/tr>\n
smith r<\/td>3.3097509196469<\/td>\n<\/tr>\n
natriuretic peptides<\/td>3.3097509196469<\/td>\n<\/tr>\n
genetic disorders<\/td>3.3097509196469<\/td>\n<\/tr>\n
careful monitoring of serum potassium levels<\/td>3.2957569692557<\/td>\n<\/tr>\n
severe cardiogenic shock<\/td>3.2598444275496<\/td>\n<\/tr>\n
current measures<\/td>3.2531531233956<\/td>\n<\/tr>\n
time-to-furosemide treatment<\/td>3.2385318404644<\/td>\n<\/tr>\n
hospital admission rate<\/td>3.2377408137211<\/td>\n<\/tr>\n
angiotensin-converting enzyme inhibitors<\/td>3.2368032890054<\/td>\n<\/tr>\n
atrial arrhythmia<\/td>3.2237097954706<\/td>\n<\/tr>\n
hospitalized patients<\/td>3.2237097954706<\/td>\n<\/tr>\n
selected patients<\/td>3.2237097954706<\/td>\n<\/tr>\n
natural history<\/td>3.2237097954706<\/td>\n<\/tr>\n
elevated levels of low-density lipoprotein cholesterol<\/td>3.2113286293254<\/td>\n<\/tr>\n
low high-density lipoprotein cholesterol levels<\/td>3.2113286293254<\/td>\n<\/tr>\n
detrimental effect of sodium restriction<\/td>3.2033666669598<\/td>\n<\/tr>\n
functional mitral regurgitation<\/td>3.2031009475288<\/td>\n<\/tr>\n
cardiopulmonary exercise testing<\/td>3.2031009475288<\/td>\n<\/tr>\n
obesity-related cardiomyopathy<\/td>3.1779718278113<\/td>\n<\/tr>\n
dilated cardiomyopathy<\/td>3.1779718278113<\/td>\n<\/tr>\n
tachycardia-induced cardiomyopathy<\/td>3.1779718278113<\/td>\n<\/tr>\n
diabetic cardiomyopathy<\/td>3.1779718278113<\/td>\n<\/tr>\n
eplerenone group<\/td>3.1779718278113<\/td>\n<\/tr>\n
hypertrophic cardiomyopathy<\/td>3.1779718278113<\/td>\n<\/tr>\n
ordinary physical activity results<\/td>3.1616447614742<\/td>\n<\/tr>\n
prediction of survival<\/td>3.1463462836458<\/td>\n<\/tr>\n
expected survival<\/td>3.1463462836458<\/td>\n<\/tr>\n
survival advantage<\/td>3.1463462836458<\/td>\n<\/tr>\n
meaningful survival<\/td>3.1463462836458<\/td>\n<\/tr>\n
noninvasive imaging<\/td>3.1301691601466<\/td>\n<\/tr>\n
long-term use<\/td>3.1301691601466<\/td>\n<\/tr>\n
aborted cardiac arrest<\/td>3.1231391134797<\/td>\n<\/tr>\n
smith al<\/td>3.1054227990715<\/td>\n<\/tr>\n
structured cardiac rehabilitation program<\/td>3.0918884056739<\/td>\n<\/tr>\n
high doses<\/td>3.080070288241<\/td>\n<\/tr>\n
large multicenter<\/td>3.080070288241<\/td>\n<\/tr>\n
nt-probnp levels<\/td>3.080070288241<\/td>\n<\/tr>\n
thiazide diuretic<\/td>3.080070288241<\/td>\n<\/tr>\n
electrolyte levels<\/td>3.080070288241<\/td>\n<\/tr>\n
current aha guidelines<\/td>3.0668124740328<\/td>\n<\/tr>\n
yancy c<\/td>3.0628143136088<\/td>\n<\/tr>\n
other genetic disorders of iron metabolism<\/td>3.0600833060707<\/td>\n<\/tr>\n
different types of care<\/td>3.0569032462135<\/td>\n<\/tr>\n
elevated jugular venous pressure<\/td>3.0400841363597<\/td>\n<\/tr>\n
systemic disorder<\/td>3.0274001040351<\/td>\n<\/tr>\n
practice improvement<\/td>3.0274001040351<\/td>\n<\/tr>\n
systemic diseases<\/td>3.0274001040351<\/td>\n<\/tr>\n
iron overload<\/td>3.0274001040351<\/td>\n<\/tr>\n
daily weight checks<\/td>3.0261714988458<\/td>\n<\/tr>\n
iervasi g. thyroid replacement therapy<\/td>3.0061164174793<\/td>\n<\/tr>\n
natriuretic peptide-based screening<\/td>2.9937951655239<\/td>\n<\/tr>\n
observational studies<\/td>2.9906975624424<\/td>\n<\/tr>\n
doukky r<\/td>2.9906975624424<\/td>\n<\/tr>\n
segal r<\/td>2.9906975624424<\/td>\n<\/tr>\n
quigg r<\/td>2.9906975624424<\/td>\n<\/tr>\n
comenzo r<\/td>2.9906975624424<\/td>\n<\/tr>\n
quality indicators<\/td>2.9906975624424<\/td>\n<\/tr>\n
marchioli r<\/td>2.9906975624424<\/td>\n<\/tr>\n
davies r<\/td>2.9906975624424<\/td>\n<\/tr>\n
lieberman r<\/td>2.9906975624424<\/td>\n<\/tr>\n
cody r<\/td>2.9906975624424<\/td>\n<\/tr>\n
deo r<\/td>2.9906975624424<\/td>\n<\/tr>\n
cremo r<\/td>2.9906975624424<\/td>\n<\/tr>\n
amirnovin r<\/td>2.9906975624424<\/td>\n<\/tr>\n
physical activities<\/td>2.9718278662008<\/td>\n<\/tr>\n
physical exam<\/td>2.9718278662008<\/td>\n<\/tr>\n
physical therapists<\/td>2.9718278662008<\/td>\n<\/tr>\n
predictors of mortality<\/td>2.9525917237372<\/td>\n<\/tr>\n
laboratory tests<\/td>2.9428309563827<\/td>\n<\/tr>\n
such reversible cardiac conditions<\/td>2.9390867394432<\/td>\n<\/tr>\n
hospital readmission rates<\/td>2.9355985352441<\/td>\n<\/tr>\n
long-term inotropic infusion<\/td>2.9279034960725<\/td>\n<\/tr>\n
specific structural abnormalities<\/td>2.9279034960725<\/td>\n<\/tr>\n
physician quality reporting system<\/td>2.9278526754426<\/td>\n<\/tr>\n
riegel b<\/td>2.9129506302439<\/td>\n<\/tr>\n
history of angioedema<\/td>2.9129506302439<\/td>\n<\/tr>\n
end-of-life management<\/td>2.9129506302439<\/td>\n<\/tr>\n
olofsson b<\/td>2.9129506302439<\/td>\n<\/tr>\n
increased bnp<\/td>2.9129506302439<\/td>\n<\/tr>\n
levin b<\/td>2.9129506302439<\/td>\n<\/tr>\n
eliasson b<\/td>2.9129506302439<\/td>\n<\/tr>\n
symptom management<\/td>2.9129506302439<\/td>\n<\/tr>\n
roniker b<\/td>2.9129506302439<\/td>\n<\/tr>\n
significant data<\/td>2.9129506302439<\/td>\n<\/tr>\n
wilkoff b<\/td>2.9129506302439<\/td>\n<\/tr>\n
claggett b<\/td>2.9129506302439<\/td>\n<\/tr>\n
diastolic relaxation<\/td>2.9129506302439<\/td>\n<\/tr>\n
reduced hospitalizations<\/td>2.8925076085191<\/td>\n<\/tr>\n
unexplained weight gain<\/td>2.8844991406148<\/td>\n<\/tr>\n
angiotensin-receptor blocker valsartan<\/td>2.8844991406148<\/td>\n<\/tr>\n
intensive hypertension control<\/td>2.8844991406148<\/td>\n<\/tr>\n
lot of weight gain<\/td>2.8844991406148<\/td>\n<\/tr>\n
angiotensin-converting-enzyme inhibitors<\/td>2.882121417102<\/td>\n<\/tr>\n
acute exacerbations<\/td>2.8716217110259<\/td>\n<\/tr>\n
placebo group<\/td>2.8716217110259<\/td>\n<\/tr>\n
sacubitril?valsartan group<\/td>2.8716217110259<\/td>\n<\/tr>\n
epicardial coronary arteries<\/td>2.8536385282275<\/td>\n<\/tr>\n
thyroid-stimulating hormone levels<\/td>2.8536385282275<\/td>\n<\/tr>\n
maggioni a<\/td>2.8502698827718<\/td>\n<\/tr>\n
left ventricle<\/td>2.8502698827718<\/td>\n<\/tr>\n
outpatient dose<\/td>2.8284271247462<\/td>\n<\/tr>\n
routine use<\/td>2.8284271247462<\/td>\n<\/tr>\n
ordinary activity<\/td>2.8284271247462<\/td>\n<\/tr>\n
selective aldosterone blocker<\/td>2.8210130123402<\/td>\n<\/tr>\n
combination of isosorbide dinitrate<\/td>2.8077989890847<\/td>\n<\/tr>\n
taylor al<\/td>2.8060662632967<\/td>\n<\/tr>\n
symptomatic bradycardia<\/td>2.7831576837137<\/td>\n<\/tr>\n
diuretic effectiveness<\/td>2.7831576837137<\/td>\n<\/tr>\n
lee ds<\/td>2.7831576837137<\/td>\n<\/tr>\n
diuretic strategies<\/td>2.7831576837137<\/td>\n<\/tr>\n
diuretic adjustments<\/td>2.7831576837137<\/td>\n<\/tr>\n
\u00c3\u00a0-blockers carvedilol<\/td>2.7831576837137<\/td>\n<\/tr>\n
biomarker intensified treatment<\/td>2.7578805125536<\/td>\n<\/tr>\n
overall mortality<\/td>2.7476962050545<\/td>\n<\/tr>\n
structured aerobic exercise program<\/td>2.746743631666<\/td>\n<\/tr>\n
liver function<\/td>2.7355647997348<\/td>\n<\/tr>\n
rosengren a. glycaemic control<\/td>2.7285232036427<\/td>\n<\/tr>\n
levy d<\/td>2.7108060108295<\/td>\n<\/tr>\n
atrial abnormality<\/td>2.7108060108295<\/td>\n<\/tr>\n
important characteristics<\/td>2.7108060108295<\/td>\n<\/tr>\n
important organs<\/td>2.7108060108295<\/td>\n<\/tr>\n
long-term safety<\/td>2.7108060108295<\/td>\n<\/tr>\n
wide range of causes<\/td>2.6960123091946<\/td>\n<\/tr>\n
nonvalvular atrial fibrillation<\/td>2.6889452937027<\/td>\n<\/tr>\n
shift investigators<\/td>2.6853496142827<\/td>\n<\/tr>\n
topcat investigators<\/td>2.6853496142827<\/td>\n<\/tr>\n
paradigm-hf investigators<\/td>2.6853496142827<\/td>\n<\/tr>\n
warcef investigators<\/td>2.6853496142827<\/td>\n<\/tr>\n
gissi-hf investigators<\/td>2.6853496142827<\/td>\n<\/tr>\n
hf-action investigators<\/td>2.6853496142827<\/td>\n<\/tr>\n
hope investigators<\/td>2.6853496142827<\/td>\n<\/tr>\n
acute dyspnea<\/td>2.6723451177838<\/td>\n<\/tr>\n
formal exercise programs<\/td>2.66716827534<\/td>\n<\/tr>\n
other shunts<\/td>2.6591479484725<\/td>\n<\/tr>\n
le helloco a<\/td>2.6571971456127<\/td>\n<\/tr>\n
elkayam u. peripartum cardiomyopathy<\/td>2.6521704180372<\/td>\n<\/tr>\n
v-heft va cooperative studies group<\/td>2.6379831394264<\/td>\n<\/tr>\n
tolerated dose<\/td>2.632148025905<\/td>\n<\/tr>\n
significant reductions<\/td>2.632148025905<\/td>\n<\/tr>\n
last dose<\/td>2.632148025905<\/td>\n<\/tr>\n
sodium intake<\/td>2.632148025905<\/td>\n<\/tr>\n
significant reduction<\/td>2.632148025905<\/td>\n<\/tr>\n
angiotensin-receptor blocker<\/td>2.632148025905<\/td>\n<\/tr>\n
elevated bnp<\/td>2.632148025905<\/td>\n<\/tr>\n
current medications<\/td>2.632148025905<\/td>\n<\/tr>\n
ann intern med<\/td>2.6207413942089<\/td>\n<\/tr>\n
selective aldosterone antagonist<\/td>2.6084654714896<\/td>\n<\/tr>\n
several consensus guidelines<\/td>2.6043085235871<\/td>\n<\/tr>\n
heterogeneous group of outpatients<\/td>2.5958936998277<\/td>\n<\/tr>\n
hemodynamic monitoring<\/td>2.5900200641113<\/td>\n<\/tr>\n
cushman m<\/td>2.5900200641113<\/td>\n<\/tr>\n
baggett c<\/td>2.5755095769014<\/td>\n<\/tr>\n
avezum a<\/td>2.5755095769014<\/td>\n<\/tr>\n
perez a<\/td>2.5755095769014<\/td>\n<\/tr>\n
rapezzi c<\/td>2.5755095769014<\/td>\n<\/tr>\n
chavelas c<\/td>2.5755095769014<\/td>\n<\/tr>\n
kiran a<\/td>2.5755095769014<\/td>\n<\/tr>\n
dan a<\/td>2.5755095769014<\/td>\n<\/tr>\n
barth c<\/td>2.5755095769014<\/td>\n<\/tr>\n
dyer a<\/td>2.5755095769014<\/td>\n<\/tr>\n
yilmaz a<\/td>2.5755095769014<\/td>\n<\/tr>\n
shi h<\/td>2.5755095769014<\/td>\n<\/tr>\n
castaigne a<\/td>2.5755095769014<\/td>\n<\/tr>\n
mangla a<\/td>2.5755095769014<\/td>\n<\/tr>\n
henrick a<\/td>2.5755095769014<\/td>\n<\/tr>\n
dubost-brama a<\/td>2.5755095769014<\/td>\n<\/tr>\n
laupacis a<\/td>2.5755095769014<\/td>\n<\/tr>\n
kopp a<\/td>2.5755095769014<\/td>\n<\/tr>\n
ukena c<\/td>2.5755095769014<\/td>\n<\/tr>\n
avogaro a<\/td>2.5755095769014<\/td>\n<\/tr>\n
conlon c<\/td>2.5755095769014<\/td>\n<\/tr>\n
kadish a<\/td>2.5755095769014<\/td>\n<\/tr>\n
glomerular filtration rate<\/td>2.5697965868507<\/td>\n<\/tr>\n
tolerated dose of \u00c3\u00a0-blockers<\/td>2.5697965868507<\/td>\n<\/tr>\n
intravenous bolus<\/td>2.5457298950218<\/td>\n<\/tr>\n
definitive evidence<\/td>2.5457298950218<\/td>\n<\/tr>\n
strong evidence<\/td>2.5457298950218<\/td>\n<\/tr>\n
aldosterone antagonists<\/td>2.5457298950218<\/td>\n<\/tr>\n
causative factors<\/td>2.5457298950218<\/td>\n<\/tr>\n
digitalis investigation group<\/td>2.5454319088428<\/td>\n<\/tr>\n
short-term symptomatic benefits<\/td>2.5423029068338<\/td>\n<\/tr>\n
used loop diuretics<\/td>2.5132368765511<\/td>\n<\/tr>\n
parasuraman s. glycemic control<\/td>2.5020668097181<\/td>\n<\/tr>\n
in-hospital mortality<\/td>2.4828237961984<\/td>\n<\/tr>\n
physician quality reporting initiative?that clinicians<\/td>2.4754341287137<\/td>\n<\/tr>\n
overt cardiogenic shock<\/td>2.4662120743305<\/td>\n<\/tr>\n
rapid b-natriuretic peptide assay<\/td>2.4494897427832<\/td>\n<\/tr>\n
advanced therapies<\/td>2.4494897427832<\/td>\n<\/tr>\n
primary outcome<\/td>2.4494897427832<\/td>\n<\/tr>\n
kavalieratos d<\/td>2.4494897427832<\/td>\n<\/tr>\n
logeart d<\/td>2.4494897427832<\/td>\n<\/tr>\n
same population<\/td>2.4494897427832<\/td>\n<\/tr>\n
lifestyle modifications<\/td>2.4494897427832<\/td>\n<\/tr>\n
aguilar d<\/td>2.4494897427832<\/td>\n<\/tr>\n
johnstone d<\/td>2.4494897427832<\/td>\n<\/tr>\n
ettehad d<\/td>2.4494897427832<\/td>\n<\/tr>\n
mozaffarian d<\/td>2.4494897427832<\/td>\n<\/tr>\n
gras d<\/td>2.4494897427832<\/td>\n<\/tr>\n
valvular abnormalities<\/td>2.4322992790978<\/td>\n<\/tr>\n
joshua-gotlib s<\/td>2.4147364027664<\/td>\n<\/tr>\n
franz?n s<\/td>2.4147364027664<\/td>\n<\/tr>\n
kuroda s<\/td>2.4147364027664<\/td>\n<\/tr>\n
homma s<\/td>2.4147364027664<\/td>\n<\/tr>\n
ziesche s<\/td>2.4147364027664<\/td>\n<\/tr>\n
gudbj?rnsdottir s<\/td>2.4147364027664<\/td>\n<\/tr>\n
non?left bundle branch block pattern<\/td>2.3924623977026<\/td>\n<\/tr>\n
carson p<\/td>2.3784142300054<\/td>\n<\/tr>\n
clopton p<\/td>2.3784142300054<\/td>\n<\/tr>\n
severe comorbidities<\/td>2.3784142300054<\/td>\n<\/tr>\n
maximum dose<\/td>2.3784142300054<\/td>\n<\/tr>\n
beyne p<\/td>2.3784142300054<\/td>\n<\/tr>\n
severe signs<\/td>2.3784142300054<\/td>\n<\/tr>\n
sleight p<\/td>2.3784142300054<\/td>\n<\/tr>\n
gueffet p<\/td>2.3784142300054<\/td>\n<\/tr>\n
use age<\/td>2.3784142300054<\/td>\n<\/tr>\n
elliott p<\/td>2.3784142300054<\/td>\n<\/tr>\n
mohacsi p<\/td>2.3784142300054<\/td>\n<\/tr>\n
afterload-reducing agents<\/td>2.3784142300054<\/td>\n<\/tr>\n
duc p<\/td>2.3784142300054<\/td>\n<\/tr>\n
dennison himmelfarb c<\/td>2.3672935308725<\/td>\n<\/tr>\n
terms gcardiomyopathy h<\/td>2.3672935308725<\/td>\n<\/tr>\n
dei cas a<\/td>2.3672935308725<\/td>\n<\/tr>\n
systemic lupus erythematosus<\/td>2.3490100793233<\/td>\n<\/tr>\n
continuous intravenous administration<\/td>2.3490100793233<\/td>\n<\/tr>\n
multicenter guide-it<\/td>2.3403473193207<\/td>\n<\/tr>\n
komajda m<\/td>2.3403473193207<\/td>\n<\/tr>\n
lenski m<\/td>2.3403473193207<\/td>\n<\/tr>\n
miftaraj m<\/td>2.3403473193207<\/td>\n<\/tr>\n
diagnostic tests<\/td>2.3403473193207<\/td>\n<\/tr>\n
lind m<\/td>2.3403473193207<\/td>\n<\/tr>\n
b?hm m<\/td>2.3403473193207<\/td>\n<\/tr>\n
fiuzat m<\/td>2.3403473193207<\/td>\n<\/tr>\n
olsson m<\/td>2.3403473193207<\/td>\n<\/tr>\n
\u00c3\u00a0-blocker carvedilol<\/td>2.3403473193207<\/td>\n<\/tr>\n
ledwidge m<\/td>2.3403473193207<\/td>\n<\/tr>\n
semigran m<\/td>2.3403473193207<\/td>\n<\/tr>\n
electrocardiographic monitoring<\/td>2.3403473193207<\/td>\n<\/tr>\n
hospital-level 30-day mortality<\/td>2.3101522238684<\/td>\n<\/tr>\n
robust predictor of mortality<\/td>2.3101522238684<\/td>\n<\/tr>\n
oral anticoagulants<\/td>2.3003266337912<\/td>\n<\/tr>\n
nma\/pcna guideline<\/td>2.3003266337912<\/td>\n<\/tr>\n
oral torsemide<\/td>2.3003266337912<\/td>\n<\/tr>\n
patient's outpatient<\/td>2.3003266337912<\/td>\n<\/tr>\n
guiding evidence<\/td>2.3003266337912<\/td>\n<\/tr>\n
conflicting evidence<\/td>2.3003266337912<\/td>\n<\/tr>\n
optimal therapeutic range<\/td>2.2894284851067<\/td>\n<\/tr>\n
replacement device<\/td>2.2795070569548<\/td>\n<\/tr>\n
maisel a. utility<\/td>2.2449240966188<\/td>\n<\/tr>\n
hood wb jr<\/td>2.2390395117024<\/td>\n<\/tr>\n
several medications<\/td>2.2133638394006<\/td>\n<\/tr>\n
subjective assessment<\/td>2.2133638394006<\/td>\n<\/tr>\n
modification of hypertension<\/td>2.2133638394006<\/td>\n<\/tr>\n
martinez f<\/td>2.2133638394006<\/td>\n<\/tr>\n
healthcare research<\/td>2.2133638394006<\/td>\n<\/tr>\n
2-lb increase<\/td>2.2133638394006<\/td>\n<\/tr>\n
avery e<\/td>2.2133638394006<\/td>\n<\/tr>\n
5-lb increase<\/td>2.2133638394006<\/td>\n<\/tr>\n
diverse range<\/td>2.2133638394006<\/td>\n<\/tr>\n
impact of diabetes<\/td>2.2133638394006<\/td>\n<\/tr>\n
general population<\/td>2.2133638394006<\/td>\n<\/tr>\n
patient's subjective experience<\/td>2.1955146386099<\/td>\n<\/tr>\n
stroke statistics subcommittee<\/td>2.1822472719434<\/td>\n<\/tr>\n
role of lifestyle modifications<\/td>2.1822472719434<\/td>\n<\/tr>\n
deswal a. relationship of hemoglobin<\/td>2.1810154653305<\/td>\n<\/tr>\n
nonsudden death<\/td>2.165736770668<\/td>\n<\/tr>\n
hemodynamic overload<\/td>2.1406951429281<\/td>\n<\/tr>\n
thiazide diuretics<\/td>2.1406951429281<\/td>\n<\/tr>\n
tobacco use screening<\/td>2.1398263878673<\/td>\n<\/tr>\n
many genetic cardiomyopathies<\/td>2.1398263878673<\/td>\n<\/tr>\n
alternative imaging methods<\/td>2.1398263878673<\/td>\n<\/tr>\n
ojamaa k. thyroid hormone<\/td>2.1351847961967<\/td>\n<\/tr>\n
serious health condition<\/td>2.1169328630255<\/td>\n<\/tr>\n
thorgeirsson g<\/td>2.1147425268811<\/td>\n<\/tr>\n
thabut g<\/td>2.1147425268811<\/td>\n<\/tr>\n
meurers g<\/td>2.1147425268811<\/td>\n<\/tr>\n
johnson g<\/td>2.1147425268811<\/td>\n<\/tr>\n
dagenais g<\/td>2.1147425268811<\/td>\n<\/tr>\n
jondeau g<\/td>2.1147425268811<\/td>\n<\/tr>\n
ginn g<\/td>2.1147425268811<\/td>\n<\/tr>\n
noninvasive computed tomographic angiography<\/td>2.1039790110173<\/td>\n<\/tr>\n
author thanks lee r. goldberg<\/td>2.0827594879848<\/td>\n<\/tr>\n
effective gsliding h regimen<\/td>2.0812192439376<\/td>\n<\/tr>\n
djousse l<\/td>2.0597671439071<\/td>\n<\/tr>\n
hood wb<\/td>2.0597671439071<\/td>\n<\/tr>\n
tavazzi l<\/td>2.0597671439071<\/td>\n<\/tr>\n
long-term benefit<\/td>2.0597671439071<\/td>\n<\/tr>\n
damman k<\/td>2.0597671439071<\/td>\n<\/tr>\n
rapid measurement<\/td>2.0597671439071<\/td>\n<\/tr>\n
matsushita k<\/td>2.0597671439071<\/td>\n<\/tr>\n
primary prophylaxis<\/td>2.0597671439071<\/td>\n<\/tr>\n
lenert l<\/td>2.0597671439071<\/td>\n<\/tr>\n
ramasubbu k<\/td>2.0597671439071<\/td>\n<\/tr>\n
malmberg k<\/td>2.0597671439071<\/td>\n<\/tr>\n
additional medications<\/td>2.0597671439071<\/td>\n<\/tr>\n
kappenberger l<\/td>2.0597671439071<\/td>\n<\/tr>\n
angelici l<\/td>2.0597671439071<\/td>\n<\/tr>\n
ferdinand k<\/td>2.0597671439071<\/td>\n<\/tr>\n
fibrofatty replacement<\/td>2.0597671439071<\/td>\n<\/tr>\n
videb?k l<\/td>2.0597671439071<\/td>\n<\/tr>\n
2-dimensional doppler echocardiography<\/td>2.0396489026555<\/td>\n<\/tr>\n
two-dimensional doppler echocardiography<\/td>2.0396489026555<\/td>\n<\/tr>\n
additional diagnostic testing<\/td>2.0396489026555<\/td>\n<\/tr>\n
prognostic value of changes<\/td>2.0396489026555<\/td>\n<\/tr>\n
raimondi e<\/td>2<\/td>\n<\/tr>\n
korup e<\/td>2<\/td>\n<\/tr>\n
chemotherapeutic agents trastuzumab<\/td>2<\/td>\n<\/tr>\n
total distance<\/td>2<\/td>\n<\/tr>\n
tallon e<\/td>2<\/td>\n<\/tr>\n
funck f<\/td>2<\/td>\n<\/tr>\n
suspected cases<\/td>2<\/td>\n<\/tr>\n
long-standing untreated hypertension<\/td>2<\/td>\n<\/tr>\n
daubert jc<\/td>2<\/td>\n<\/tr>\n
mahfoud f<\/td>2<\/td>\n<\/tr>\n
million persons<\/td>2<\/td>\n<\/tr>\n
7.5 mg<\/td>2<\/td>\n<\/tr>\n
beauvais f<\/td>2<\/td>\n<\/tr>\n
donal e<\/td>2<\/td>\n<\/tr>\n
million hospital discharges<\/td>2<\/td>\n<\/tr>\n
hemoglobin a1c<\/td>2<\/td>\n<\/tr>\n
erdmann e<\/td>2<\/td>\n<\/tr>\n
o fconnell e<\/td>2<\/td>\n<\/tr>\n
prospective comparison of arni<\/td>2<\/td>\n<\/tr>\n
home health staff<\/td>1.9786024464679<\/td>\n<\/tr>\n
lindenfeld ja<\/td>1.9679896712654<\/td>\n<\/tr>\n
prognostic information<\/td>1.9679896712654<\/td>\n<\/tr>\n
high-risk populations<\/td>1.9679896712654<\/td>\n<\/tr>\n
combination of hydralazine<\/td>1.9679896712654<\/td>\n<\/tr>\n
downloadable guideline algorithm<\/td>1.9559811771959<\/td>\n<\/tr>\n
wall-motion abnormalities<\/td>1.9343364202677<\/td>\n<\/tr>\n
thune jj<\/td>1.9343364202677<\/td>\n<\/tr>\n
active ischemia<\/td>1.9343364202677<\/td>\n<\/tr>\n
mamdani mm<\/td>1.9343364202677<\/td>\n<\/tr>\n
redfield mm<\/td>1.9343364202677<\/td>\n<\/tr>\n
patient's circumstances<\/td>1.9343364202677<\/td>\n<\/tr>\n
teerlink jr<\/td>1.9343364202677<\/td>\n<\/tr>\n
scheinman mm<\/td>1.9343364202677<\/td>\n<\/tr>\n
glucose abnormalities<\/td>1.9343364202677<\/td>\n<\/tr>\n
colvin mm<\/td>1.9343364202677<\/td>\n<\/tr>\n
excess iron deposition<\/td>1.9063685859939<\/td>\n<\/tr>\n
long-acting metoprolol succinate<\/td>1.9063685859939<\/td>\n<\/tr>\n
implantable cardioversion defibrillation<\/td>1.9063685859939<\/td>\n<\/tr>\n
sustained efficacy<\/td>1.8612097182042<\/td>\n<\/tr>\n
goldberg lr<\/td>1.8612097182042<\/td>\n<\/tr>\n
alcohol consumption<\/td>1.8612097182042<\/td>\n<\/tr>\n
vago t<\/td>1.8612097182042<\/td>\n<\/tr>\n
efficacy of icds<\/td>1.8612097182042<\/td>\n<\/tr>\n
many areas<\/td>1.8612097182042<\/td>\n<\/tr>\n
absence of arrhythmia<\/td>1.8612097182042<\/td>\n<\/tr>\n
remme wj<\/td>1.8612097182042<\/td>\n<\/tr>\n
continuous infusion<\/td>1.8612097182042<\/td>\n<\/tr>\n
social support<\/td>1.8612097182042<\/td>\n<\/tr>\n
direct toxicity<\/td>1.8612097182042<\/td>\n<\/tr>\n
new agent<\/td>1.8612097182042<\/td>\n<\/tr>\n
first calls<\/td>1.8612097182042<\/td>\n<\/tr>\n
hardarson t<\/td>1.8612097182042<\/td>\n<\/tr>\n
routine anticoagulation<\/td>1.8612097182042<\/td>\n<\/tr>\n
definitive therapies<\/td>1.8612097182042<\/td>\n<\/tr>\n
major hemorrhage<\/td>1.8612097182042<\/td>\n<\/tr>\n
aspelund t<\/td>1.8612097182042<\/td>\n<\/tr>\n
yamaguchi t<\/td>1.8612097182042<\/td>\n<\/tr>\n
objective predictors<\/td>1.8612097182042<\/td>\n<\/tr>\n
callender t<\/td>1.8612097182042<\/td>\n<\/tr>\n
common precursor molecule<\/td>1.8493111942973<\/td>\n<\/tr>\n
composite end point<\/td>1.8493111942973<\/td>\n<\/tr>\n
regular measurement of electrolytes<\/td>1.8171205928321<\/td>\n<\/tr>\n
improved safety profiles<\/td>1.8171205928321<\/td>\n<\/tr>\n
van veldhuisen dj<\/td>1.7817974362807<\/td>\n<\/tr>\n
early postpartum period<\/td>1.7817974362807<\/td>\n<\/tr>\n
complete follow-up results<\/td>1.7817974362807<\/td>\n<\/tr>\n
several regulatory agencies<\/td>1.7817974362807<\/td>\n<\/tr>\n
review of animal models<\/td>1.7817974362807<\/td>\n<\/tr>\n
composite of time<\/td>1.7782794100389<\/td>\n<\/tr>\n
common questions<\/td>1.7782794100389<\/td>\n<\/tr>\n
preventable syndrome<\/td>1.7782794100389<\/td>\n<\/tr>\n
frequent hospitalizations<\/td>1.7782794100389<\/td>\n<\/tr>\n
combination of sacubitril<\/td>1.7782794100389<\/td>\n<\/tr>\n
heart-failure events<\/td>1.7782794100389<\/td>\n<\/tr>\n
recurrent hospitalizations<\/td>1.7782794100389<\/td>\n<\/tr>\n
neyra ja<\/td>1.7782794100389<\/td>\n<\/tr>\n
curtis jp<\/td>1.7782794100389<\/td>\n<\/tr>\n
biventricular pacing<\/td>1.7782794100389<\/td>\n<\/tr>\n
boehmer jp<\/td>1.7782794100389<\/td>\n<\/tr>\n
coats aj<\/td>1.7782794100389<\/td>\n<\/tr>\n
cowley aj<\/td>1.7782794100389<\/td>\n<\/tr>\n
peripheral edema<\/td>1.7320508075689<\/td>\n<\/tr>\n
same benefits<\/td>1.7320508075689<\/td>\n<\/tr>\n
strong muscle<\/td>1.7320508075689<\/td>\n<\/tr>\n
collins kj<\/td>1.7320508075689<\/td>\n<\/tr>\n
cushman wc<\/td>1.7320508075689<\/td>\n<\/tr>\n
aortic regurgitation<\/td>1.7320508075689<\/td>\n<\/tr>\n
maggioni ap<\/td>1.7320508075689<\/td>\n<\/tr>\n
levy wc<\/td>1.7320508075689<\/td>\n<\/tr>\n
remme w<\/td>1.7320508075689<\/td>\n<\/tr>\n
wang y<\/td>1.7320508075689<\/td>\n<\/tr>\n
stable outpatients<\/td>1.7320508075689<\/td>\n<\/tr>\n
peak oxygen consumption<\/td>1.6983813295649<\/td>\n<\/tr>\n
paroxysmal nocturnal dyspnea<\/td>1.6983813295649<\/td>\n<\/tr>\n
last trimester of pregnancy<\/td>1.6983813295649<\/td>\n<\/tr>\n
giant cell myocarditis<\/td>1.6983813295649<\/td>\n<\/tr>\n
shantsila e. anticoagulation<\/td>1.6983813295649<\/td>\n<\/tr>\n
katus ha<\/td>1.6817928305074<\/td>\n<\/tr>\n
franzosi mg<\/td>1.6817928305074<\/td>\n<\/tr>\n
whellan dj<\/td>1.6817928305074<\/td>\n<\/tr>\n
evans jc<\/td>1.6817928305074<\/td>\n<\/tr>\n
sound waves<\/td>1.6817928305074<\/td>\n<\/tr>\n
freudenberger rs<\/td>1.6817928305074<\/td>\n<\/tr>\n
one meta-analysis<\/td>1.6817928305074<\/td>\n<\/tr>\n
stress testing<\/td>1.6817928305074<\/td>\n<\/tr>\n
increases regression<\/td>1.6817928305074<\/td>\n<\/tr>\n
wilber dj<\/td>1.6817928305074<\/td>\n<\/tr>\n
muscular dystrophies<\/td>1.6817928305074<\/td>\n<\/tr>\n
white persons<\/td>1.6817928305074<\/td>\n<\/tr>\n
episodic arrhythmia<\/td>1.6817928305074<\/td>\n<\/tr>\n
ellis sj<\/td>1.6817928305074<\/td>\n<\/tr>\n
desai as<\/td>1.6817928305074<\/td>\n<\/tr>\n
packer dl<\/td>1.6817928305074<\/td>\n<\/tr>\n
qrs prolongation<\/td>1.6817928305074<\/td>\n<\/tr>\n
nielsen jc<\/td>1.6817928305074<\/td>\n<\/tr>\n
tycon le<\/td>1.6817928305074<\/td>\n<\/tr>\n
systematic review<\/td>1.6817928305074<\/td>\n<\/tr>\n
rare disorder<\/td>1.6817928305074<\/td>\n<\/tr>\n
klein hu<\/td>1.6817928305074<\/td>\n<\/tr>\n
major problem<\/td>1.6817928305074<\/td>\n<\/tr>\n
beanlands rs<\/td>1.6817928305074<\/td>\n<\/tr>\n
unpredictable exacerbations<\/td>1.6817928305074<\/td>\n<\/tr>\n
elimination of tachycardia<\/td>1.6817928305074<\/td>\n<\/tr>\n
slight limitation<\/td>1.6817928305074<\/td>\n<\/tr>\n
poor prognosis<\/td>1.6817928305074<\/td>\n<\/tr>\n
many parts<\/td>1.6817928305074<\/td>\n<\/tr>\n
black persons<\/td>1.6817928305074<\/td>\n<\/tr>\n
rheumatologic diseases<\/td>1.6817928305074<\/td>\n<\/tr>\n
ha ac<\/td>1.6817928305074<\/td>\n<\/tr>\n
cleland jg<\/td>1.6817928305074<\/td>\n<\/tr>\n
marked limitation<\/td>1.6817928305074<\/td>\n<\/tr>\n
wall thickness<\/td>1.6817928305074<\/td>\n<\/tr>\n
serial echocardiography<\/td>1.6817928305074<\/td>\n<\/tr>\n
enrollment goal<\/td>1.6817928305074<\/td>\n<\/tr>\n
drink alcohol<\/td>1.6817928305074<\/td>\n<\/tr>\n
heritable disorder<\/td>1.6817928305074<\/td>\n<\/tr>\n
vasan rs<\/td>1.6817928305074<\/td>\n<\/tr>\n
african americans<\/td>1.6817928305074<\/td>\n<\/tr>\n
ambrosius wt<\/td>1.6817928305074<\/td>\n<\/tr>\n
cochrane database syst rev<\/td>1.6817928305074<\/td>\n<\/tr>\n
wood ma<\/td>1.6817928305074<\/td>\n<\/tr>\n
dietary recommendations<\/td>1.6817928305074<\/td>\n<\/tr>\n
million people<\/td>1.6817928305074<\/td>\n<\/tr>\n
keteyian sj<\/td>1.6817928305074<\/td>\n<\/tr>\n
select therapies<\/td>1.6817928305074<\/td>\n<\/tr>\n
ellison rc<\/td>1.6817928305074<\/td>\n<\/tr>\n
inflammatory diseases<\/td>1.6817928305074<\/td>\n<\/tr>\n
suitable alternative<\/td>1.6817928305074<\/td>\n<\/tr>\n
pocock sj<\/td>1.6817928305074<\/td>\n<\/tr>\n
insoluble fibrillar proteins<\/td>1.5874010519682<\/td>\n<\/tr>\n
myocyte adipose accumulation<\/td>1.5874010519682<\/td>\n<\/tr>\n
autosomal dominant mutations<\/td>1.5874010519682<\/td>\n<\/tr>\n
complex psychosocial issues<\/td>1.5874010519682<\/td>\n<\/tr>\n
emdin ca<\/td>1.5650845800733<\/td>\n<\/tr>\n
fitzpatrick ap<\/td>1.5650845800733<\/td>\n<\/tr>\n
low-sodium diet<\/td>1.5650845800733<\/td>\n<\/tr>\n
n-terminal pro?b<\/td>1.5650845800733<\/td>\n<\/tr>\n
lower-extremity edema<\/td>1.5650845800733<\/td>\n<\/tr>\n
n-terminal pro-brain<\/td>1.5650845800733<\/td>\n<\/tr>\n
das sr<\/td>1.5650845800733<\/td>\n<\/tr>\n
rathore ss<\/td>1.5650845800733<\/td>\n<\/tr>\n
bristow mr<\/td>1.5650845800733<\/td>\n<\/tr>\n
anstrom kj<\/td>1.5650845800733<\/td>\n<\/tr>\n
former condition<\/td>1.5650845800733<\/td>\n<\/tr>\n
avery cl<\/td>1.5650845800733<\/td>\n<\/tr>\n
collins sp<\/td>1.5650845800733<\/td>\n<\/tr>\n
decrease afterload<\/td>1.5650845800733<\/td>\n<\/tr>\n
jensen dn<\/td>1.5650845800733<\/td>\n<\/tr>\n
audrey wu<\/td>1.5650845800733<\/td>\n<\/tr>\n
hollander je<\/td>1.5650845800733<\/td>\n<\/tr>\n
costanzo mr<\/td>1.5650845800733<\/td>\n<\/tr>\n
nery pb<\/td>1.5650845800733<\/td>\n<\/tr>\n
khan ss<\/td>1.5650845800733<\/td>\n<\/tr>\n
gudnason v<\/td>1.5650845800733<\/td>\n<\/tr>\n
ariti ca<\/td>1.5650845800733<\/td>\n<\/tr>\n
dr. wu<\/td>1.5650845800733<\/td>\n<\/tr>\n
shinbane js<\/td>1.5650845800733<\/td>\n<\/tr>\n
loehr lr<\/td>1.5650845800733<\/td>\n<\/tr>\n
wang tj<\/td>1.5650845800733<\/td>\n<\/tr>\n
second calls<\/td>1.5650845800733<\/td>\n<\/tr>\n
professional roles<\/td>1.5650845800733<\/td>\n<\/tr>\n
nowak rm<\/td>1.5650845800733<\/td>\n<\/tr>\n
matsue y<\/td>1.5650845800733<\/td>\n<\/tr>\n
emergency department<\/td>1.5650845800733<\/td>\n<\/tr>\n
developed areas<\/td>1.5650845800733<\/td>\n<\/tr>\n
anderson kp<\/td>1.5650845800733<\/td>\n<\/tr>\n
rizkala ar<\/td>1.5650845800733<\/td>\n<\/tr>\n
juurlink dn<\/td>1.5650845800733<\/td>\n<\/tr>\n
ann arbor<\/td>1.5650845800733<\/td>\n<\/tr>\n
nonpharmacologic interventions<\/td>1.5650845800733<\/td>\n<\/tr>\n
specialized interventions<\/td>1.5650845800733<\/td>\n<\/tr>\n
cavity size<\/td>1.5650845800733<\/td>\n<\/tr>\n
leon ar<\/td>1.5650845800733<\/td>\n<\/tr>\n
short-term basis<\/td>1.5650845800733<\/td>\n<\/tr>\n
borer js<\/td>1.5650845800733<\/td>\n<\/tr>\n
carey rm<\/td>1.5650845800733<\/td>\n<\/tr>\n
previous version<\/td>1.5650845800733<\/td>\n<\/tr>\n
enough data<\/td>1.5650845800733<\/td>\n<\/tr>\n
goldsmith sr<\/td>1.5650845800733<\/td>\n<\/tr>\n
hereditary hemochromatosis<\/td>1.5650845800733<\/td>\n<\/tr>\n
intracerebral hemorrhage<\/td>1.5650845800733<\/td>\n<\/tr>\n
overall frailty<\/td>1.5650845800733<\/td>\n<\/tr>\n
variety of antigens<\/td>1.5650845800733<\/td>\n<\/tr>\n
intracardiac device<\/td>1.5650845800733<\/td>\n<\/tr>\n
impact of obesity<\/td>1.5650845800733<\/td>\n<\/tr>\n
wilson pw<\/td>1.5650845800733<\/td>\n<\/tr>\n
nutritional supplements<\/td>1.5650845800733<\/td>\n<\/tr>\n
hypersensitivity myocarditis<\/td>1.5650845800733<\/td>\n<\/tr>\n
poole je<\/td>1.5650845800733<\/td>\n<\/tr>\n
hereditary anemias<\/td>1.5650845800733<\/td>\n<\/tr>\n
bekelman db<\/td>1.5650845800733<\/td>\n<\/tr>\n
aortic stenosis<\/td>1.5650845800733<\/td>\n<\/tr>\n
zareba w<\/td>1.5650845800733<\/td>\n<\/tr>\n
ibrahim z<\/td>1.5650845800733<\/td>\n<\/tr>\n
young jb<\/td>1.5650845800733<\/td>\n<\/tr>\n
mark db<\/td>1.5650845800733<\/td>\n<\/tr>\n
compared hydralazine<\/td>1.5650845800733<\/td>\n<\/tr>\n
plasma brain<\/td>1.5650845800733<\/td>\n<\/tr>\n
low-salt diet<\/td>1.5650845800733<\/td>\n<\/tr>\n
anderson sg<\/td>1.5650845800733<\/td>\n<\/tr>\n
various organs<\/td>1.5650845800733<\/td>\n<\/tr>\n
nutritional deficiencies<\/td>1.5650845800733<\/td>\n<\/tr>\n
arany z<\/td>1.5650845800733<\/td>\n<\/tr>\n
martinez fa<\/td>1.5650845800733<\/td>\n<\/tr>\n
professional organizations<\/td>1.5650845800733<\/td>\n<\/tr>\n
adamson pb<\/td>1.5650845800733<\/td>\n<\/tr>\n
kutyifa v<\/td>1.5650845800733<\/td>\n<\/tr>\n
allergic reaction<\/td>1.4142135623731<\/td>\n<\/tr>\n
michelson el<\/td>1.4142135623731<\/td>\n<\/tr>\n
bonow ro<\/td>1.4142135623731<\/td>\n<\/tr>\n
vision disturbances<\/td>1.4142135623731<\/td>\n<\/tr>\n
leip ep<\/td>1.4142135623731<\/td>\n<\/tr>\n
gottlieb so<\/td>1.4142135623731<\/td>\n<\/tr>\n
cropp ab<\/td>1.4142135623731<\/td>\n<\/tr>\n
cool extremities<\/td>1.4142135623731<\/td>\n<\/tr>\n
sinoatrial node<\/td>1.4142135623731<\/td>\n<\/tr>\n
walsh cr<\/td>1.4142135623731<\/td>\n<\/tr>\n
painful gynecomastia<\/td>1.4142135623731<\/td>\n<\/tr>\n
krumholz hm<\/td>1.4142135623731<\/td>\n<\/tr>\n
arnold jm<\/td>1.4142135623731<\/td>\n<\/tr>\n
urgent-care setting<\/td>1.4142135623731<\/td>\n<\/tr>\n
unrealistic expectations<\/td>1.4142135623731<\/td>\n<\/tr>\n
medicaid services<\/td>1.4142135623731<\/td>\n<\/tr>\n
fowler mb<\/td>1.4142135623731<\/td>\n<\/tr>\n
angiotensin-neprilysin inhibition<\/td>1.4142135623731<\/td>\n<\/tr>\n
mayo clinic<\/td>1.4142135623731<\/td>\n<\/tr>\n
congenital lesions<\/td>1.4142135623731<\/td>\n<\/tr>\n
aronow ws<\/td>1.4142135623731<\/td>\n<\/tr>\n
bates jt<\/td>1.4142135623731<\/td>\n<\/tr>\n
painless procedure<\/td>1.4142135623731<\/td>\n<\/tr>\n
past decade<\/td>1.4142135623731<\/td>\n<\/tr>\n
estes na<\/td>1.4142135623731<\/td>\n<\/tr>\n
collado fm<\/td>1.4142135623731<\/td>\n<\/tr>\n
zhang zm<\/td>1.4142135623731<\/td>\n<\/tr>\n
expert opinion<\/td>1.4142135623731<\/td>\n<\/tr>\n
chiuve se<\/td>1.4142135623731<\/td>\n<\/tr>\n
heavy toll<\/td>1.4142135623731<\/td>\n<\/tr>\n
hazard ratio<\/td>1.4142135623731<\/td>\n<\/tr>\n
thompson jl<\/td>1.4142135623731<\/td>\n<\/tr>\n
effort intolerance<\/td>1.4142135623731<\/td>\n<\/tr>\n
influenza immunization<\/td>1.4142135623731<\/td>\n<\/tr>\n
thiamine deficiency<\/td>1.4142135623731<\/td>\n<\/tr>\n
predetermined threshold<\/td>1.4142135623731<\/td>\n<\/tr>\n
predicted distances<\/td>1.4142135623731<\/td>\n<\/tr>\n
industrialized countries<\/td>1.4142135623731<\/td>\n<\/tr>\n
university of michigan<\/td>1.4142135623731<\/td>\n<\/tr>\n
assmann sf<\/td>1.4142135623731<\/td>\n<\/tr>\n
ellenbogen ka<\/td>1.4142135623731<\/td>\n<\/tr>\n
smoke cigarettes<\/td>1.4142135623731<\/td>\n<\/tr>\n
progressive weakness<\/td>1.4142135623731<\/td>\n<\/tr>\n
gelfman lp<\/td>1.4142135623731<\/td>\n<\/tr>\n
linker dt<\/td>1.4142135623731<\/td>\n<\/tr>\n
bonus payments<\/td>1.4142135623731<\/td>\n<\/tr>\n
pullicino pm<\/td>1.4142135623731<\/td>\n<\/tr>\n
bardy gh<\/td>1.4142135623731<\/td>\n<\/tr>\n
maurer ms<\/td>1.4142135623731<\/td>\n<\/tr>\n
lefkowitz mp<\/td>1.4142135623731<\/td>\n<\/tr>\n
endomyocardial biopsy<\/td>1.4142135623731<\/td>\n<\/tr>\n
gruppo italiano<\/td>1.4142135623731<\/td>\n<\/tr>\n
noncaseating granulomata<\/td>1.4142135623731<\/td>\n<\/tr>\n
ikejiani dz<\/td>1.4142135623731<\/td>\n<\/tr>\n
place chairs<\/td>1.4142135623731<\/td>\n<\/tr>\n
sex-specific equations<\/td>1.4142135623731<\/td>\n<\/tr>\n
repeated transfusions<\/td>1.4142135623731<\/td>\n<\/tr>\n
viable myocardium<\/td>1.4142135623731<\/td>\n<\/tr>\n
reasonable expectation<\/td>1.4142135623731<\/td>\n<\/tr>\n
soliman ez<\/td>1.4142135623731<\/td>\n<\/tr>\n
loeb hs<\/td>1.4142135623731<\/td>\n<\/tr>\n
daniels lb<\/td>1.4142135623731<\/td>\n<\/tr>\n
swollen feet<\/td>1.4142135623731<\/td>\n<\/tr>\n
radionuclide ventriculography<\/td>1.4142135623731<\/td>\n<\/tr>\n
fconnor cm<\/td>1.4142135623731<\/td>\n<\/tr>\n
bull da<\/td>1.4142135623731<\/td>\n<\/tr>\n
euthyroid state<\/td>1.4142135623731<\/td>\n<\/tr>\n
albert nm<\/td>1.4142135623731<\/td>\n<\/tr>\n
speed of absorption<\/td>1.4142135623731<\/td>\n<\/tr>\n
poulin mf<\/td>1.4142135623731<\/td>\n<\/tr>\n
attractive possibility<\/td>1.4142135623731<\/td>\n<\/tr>\n
sutradhar sc<\/td>1.4142135623731<\/td>\n<\/tr>\n
characteristic presentation<\/td>1.4142135623731<\/td>\n<\/tr>\n
shown promise<\/td>1.4142135623731<\/td>\n<\/tr>\n
drazner mh<\/td>1.4142135623731<\/td>\n<\/tr>\n
straight line<\/td>1.4142135623731<\/td>\n<\/tr>\n
blaha mj<\/td>1.4142135623731<\/td>\n<\/tr>\n
mentz rj<\/td>1.4142135623731<\/td>\n<\/tr>\n
cleavage products<\/td>1.4142135623731<\/td>\n<\/tr>\n
journal circulation<\/td>1.4142135623731<\/td>\n<\/tr>\n
voors aa<\/td>1.4142135623731<\/td>\n<\/tr>\n
adams kf<\/td>1.4142135623731<\/td>\n<\/tr>\n
cooper ls<\/td>1.4142135623731<\/td>\n<\/tr>\n
extent of disability<\/td>1.4142135623731<\/td>\n<\/tr>\n
abdominal bloating<\/td>1.4142135623731<\/td>\n<\/tr>\n
chang pp<\/td>1.4142135623731<\/td>\n<\/tr>\n
austin pc<\/td>1.4142135623731<\/td>\n<\/tr>\n
healthy adults<\/td>1.4142135623731<\/td>\n<\/tr>\n
tool kit<\/td>1.4142135623731<\/td>\n<\/tr>\n
dao q<\/td>1.4142135623731<\/td>\n<\/tr>\n
squire ib<\/td>1.4142135623731<\/td>\n<\/tr>\n
prior chemotherapy<\/td>1.4142135623731<\/td>\n<\/tr>\n
whelton pk<\/td>1.4142135623731<\/td>\n<\/tr>\n
nichols ga<\/td>1.4142135623731<\/td>\n<\/tr>\n
dargie hj<\/td>1.4142135623731<\/td>\n<\/tr>\n
birnie dh<\/td>1.4142135623731<\/td>\n<\/tr>\n
future priorities<\/td>1.4142135623731<\/td>\n<\/tr>\n
morrison lk<\/td>1.4142135623731<\/td>\n<\/tr>\n
educational material<\/td>1.4142135623731<\/td>\n<\/tr>\n
self-care guide<\/td>1.4142135623731<\/td>\n<\/tr>\n
lip gy<\/td>1.4142135623731<\/td>\n<\/tr>\n
striated muscles<\/td>1.4142135623731<\/td>\n<\/tr>\n
anorexia nervosa<\/td>1.4142135623731<\/td>\n<\/tr>\n
executive summary<\/td>1.4142135623731<\/td>\n<\/tr>\n
obvious explanation<\/td>1.4142135623731<\/td>\n<\/tr>\n
anker sd<\/td>1.4142135623731<\/td>\n<\/tr>\n
neurohormonal activation<\/td>1.4142135623731<\/td>\n<\/tr>\n
j.jacc .2016.03.605<\/td>1<\/td>\n<\/tr>\n
.0 b013e31829e8807<\/td>1<\/td>\n<\/tr>\n
1.2 ng\/ml<\/td>1<\/td>\n<\/tr>\n
0.8 ng\/ml<\/td>1<\/td>\n<\/tr>\n
2.5 times<\/td>1<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[],"class_list":["post-2429","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"aioseo_notices":[],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p9nUTT-Db","jetpack_likes_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/posts\/2429","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/comments?post=2429"}],"version-history":[{"count":1,"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/posts\/2429\/revisions"}],"predecessor-version":[{"id":2430,"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/posts\/2429\/revisions\/2430"}],"wp:attachment":[{"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/media?parent=2429"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/categories?post=2429"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/tags?post=2429"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}